

Histology-informed liver diffusion MRI: biophysical model design and demonstration in cancer immunotherapy

Francesco Grussu^{1*}, Kinga Bernatowicz¹, Marco Palombo^{2,3}, Irene Casanova-Salas¹, Ignasi Barba^{1,4}, Sara Simonetti¹, Garazi Serna¹, Athanasios Grigoriou^{1,5}, Anna Voronova^{1,5}, Valezka Garay⁶, Juan Francisco Corral^{7,8}, Marta Vidorreta⁹, Pablo García-Polo García¹⁰, Xavier Merino^{7,8}, Richard Mast^{7,8}, Núria Roson^{7,8}, Manuel Escobar^{7,8}, Maria Vieito¹¹, Rodrigo Toledo¹, Paolo Nuciforo¹, Joaquin Mateo¹¹, Elena Garralda¹¹, Raquel Perez-Lopez^{1*}

10	
11	*Corresponding authors. Email: fgrussu@vhio.net (F.G.), rperez@vhio.net (R.P.L.)
12	
13	¹ Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital
14	Campus, Spain
15	² Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology,
16	Cardiff University, Cardiff, United Kingdom
17	³ School of Computer Science and Informatics, Cardiff University, Cardiff, UK
18	⁴ University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain
19	⁵ Department of Biomedicine, Faculty of Medicine and Health Sciences, University of
20	Barcelona, Barcelona, Spain
21	⁶ PET/MR Unit, CETIR-ASCIRES, Barcelona, Spain
22	⁷ Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
23	⁸ Institut de Diagnòstic per la Imatge (IDI), Barcelona, Spain
24	⁹ Siemens Healthineers, Madrid, Spain
25	¹⁰ GE HealthCare, Madrid, Spain
26	¹¹ Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron
27	Institute of Oncology (VHIO), Spain
28	
29	
30	Abstract

Innovative diffusion Magnetic Resonance Imaging (dMRI) models enable in vivo mapping of biologically meaningful properties such as cell size, potential biomarkers in cancer. However, while cancers frequently spread to the liver, models tailored for liver applications and easy to deploy in the clinic are still sought. We tackle this unmet need by delivering a practical and clinically viable liver dMRI modelling framework. Through direct comparison of candidate dMRI approaches in mouse models and cancer patients' data, we select a model of intra-cellular diffusion fitted to highly diffusion-weighted images, as it provides the strongest radiological-histological correlates. We demonstrate the potential application of the proposed model in cancer immunotherapy, stratifying the risk of progression based on baseline tumour cell size/density from dMRI. This result, heretofore unreported and not achievable with standard dMRI indices (e.g., apparent diffusion coefficient), suggests that our approach may become a useful tool for precision imaging in oncology.

51 Introduction

Routine clinical Magnetic Resonance Imaging (MRI) focusses on visualising macroscopic 52 pathological anatomical features, as presence of tumours. Nonetheless, MRI also offers the 53 possibility of measuring statistics of key biological properties within each pixel of a three-54 dimensional (3D) scan - known as voxel. This approach, usually referred to as quantitative 55 MRI (qMRI) (1), involves the acquisition of multiple images, each featuring a different 56 contrast, which are then analysed jointly with a mathematical model. gMRI provides 57 58 promising metrics, which could become quantitative biomarkers complementing the qualitative assessment by the expert radiologist (2). Within the qMRI landscape, diffusion 59 MRI (dMRI) refers to a subset of methods that sensitise the signal to water diffusion with 60 magnetic field gradients (1, 3, 4). Since diffusion in biological tissues is influenced by the 61 cellular microenvironment where diffusion takes place, dMRI ultimately enables the 62 indirect estimation of properties at the micrometric scale (5), such as the size of cells 63 restricting water (6, 7), thus bridging the gap between macroscopic and microscopic 64 imaging. Promising dMRI approaches have been demonstrated in virtually any region of 65 the body, including but not limited to: brain (5), spinal cord (8), prostate (6), or breast (9). 66

Innovative dMRI techniques are also urgently needed in abdominal imaging, as in liver MRI 67 (10, 11). The liver is a frequent site for cancer metastasisation (12), and liver tumours are 68 common targets for treatment response assessment in oncology. However, current response 69 criteria such as RECIST (13) have limitations, in that they rely on MRI or computed 70 tomography (CT) merely to measure tumour size, without accounting for changes under 71 therapy at the cellular level. Novel dMRI metrics could enable the characterisation of cancer 72 microenvironment over large areas, shedding light on the composition of tumours that 73 cannot be biopsied. The new readouts could also provide information on tumour 74 heterogeneity, relevant in the development of treatment resistance (14, 15), and could better 75 stratify patients eligible for treatments as immunotherapy (16), given the challenge of 76 predicting which patients can practically benefit from this innovative class of drugs (17). 77 This would be a major advancement in oncology, as it may allow for personalised treatment 78 79 planning, reductions in sample sizes in clinical trials, and ultimately improve patient outcomes (18). 80

The most recent biophysical dMRI techniques describe the non-vascular liver tissue signal 81 as the sum of contributions from intra-cellular and extra-cellular water (19-21). While these 82 models provide promising readouts of tumour microenvironments (22), their practical use 83 in real-world settings is made unfeasible by i) the high number of dMRI images (and hence 84 long scan time) required for model fitting, and by ii) the availability of specialised dMRI 85 acquisitions (23), beyond standard examinations that MRI manufactures make available in 86 the scanner console. In this study we aim to tackle this unmet need by delivering a practical 87 liver dMRI signal model that is truly feasible in hospital settings, i.e., on 1.5T or 3T systems, 88 with scan time that does not exceed 15 minutes, and using vendor-provided dMRI 89 sequences. With this objective in mind, we embraced the latest "histology-informed" dMRI 90 91 development framework, which is based on informing signal model design with co-localised histological information. The framework has shown promise in delivering dMRI approaches 92 with unprecedented fidelity to cytoarchitecture (24, 25), ensuring the biological specificity 93 of the newly designed techniques (26). 94

In this article, we aimed to identify a practical mathematicl models that maximises the agreement of dMRI estimates of metrics such as cell size to their underlying biological counterparts as seen in histology. We analysed a rich data set of dMRI scans and co-

localised hematoxylin and eosin (HE)-stained images from excised mouse livers and 98 99 patients' liver biopsies. We used this data to select the model maximising radiologicalhistological correlations, corroborating results with computer simulations. Afterwards, we 100 demonstrated the clinical utility of the designed approach in one exemplificatory response 101 assessment task, in patients suffering from advanced solid tumours and treated with 102 immunotherapy. This involved the stratification of the probability of progression under 103 treatment from baseline dMRI scans, as this is still a urgent need, given the lack of robust 104 predictors of treatment response for this class of drugs (17). In summary, our study delivers 105 a liver dMRI approach that offers metrics with high fidelity to histopathology, and which is 106 feasible in the clinic. The proposed method, based on a signal model consisting of a single 107 compartment of restricted, intra-cellular diffusion fitted to highly diffusion-weighted (DW) 108 images, identified which patients progress faster given baseline dMRI scans acquired before 109 starting immunotherapy. These results, while exploratory and requiring confirmation by 110 future studies, suggest that our dMRI framework could provide complementary information 111 to current standard-of-care imaging, playing a key role in oncology research and practice. 112

113 **Results**

114 115

137

5 **Overview: data set**

Fig. 1 illustrates the data used in this study. We will refer to data obtained in fixed mouse livers as *preclinical*. We will instead refer to data obtained in cancer patients as *clinical*.

118 Preclinical data consists of pulsed gradient spin echo (PGSE) DW MRI scans of seven fixed 119 mouse livers, performed ex vivo on a 9.4T Bruker system. It also includes whole-organ HE-120 stained sections, obtained at known radiographic position. We studied the livers of mice 121 sacrificed as part of xenograft model development in prostate cancer studies. Six had been 122 implanted with biopsies of prostate cancer patients, while one had not had any implantation. 123 While the livers from the implanted mice did not grow any tumours, they feature a variety 124 of pathologies that generated three unique histopathological phenotypes (Fig. S1). The liver 125 from the mouse with no implantation instead features normal liver structures, and we will 126 refer to it as *Control*. Of the six implanted cases, two also show normal liver tissue, with 127 representation of all normal hepatic structures. We will refer to these two cases as Pat_{NAI} 128 and Pat_{NA2} (patient biopsy implantation, but normal appearing). Another case exhibits 129 generalised necrosis and diffuse acute and chronic inflammation surrounding necrotic areas, 130 with presence of occluded thrombotic vessels. This specimen will be identified as Patnec 131 (patient biopsy implantation, with necrosis). Finally, three specimens feature an immature, 132 lymphoproliferative process, with various degrees of infiltration of small, lymphoid, 133 atypical cells with abundant mitosis, which infiltrate portal vessels and sinusoidal 134 capillaries, but without producing tumours. These cases will be referred to as Patinf1 to Patinf3 135 (patient biopsy implantation, with lymphoid cell infiltration). 136


We obtained clinical data on cancer patients suffering from advanced solid tumours, 138 139 participating in an ongoing imaging study at the Vall d'Hebron Institute of Oncology (VHIO) of Barcelona (Spain). The study involves the acquisition of MRI data, alongside 140 clinical and biological information (e.g., biopsies), in patients potentially eligible for a phase 141 I immunotherapy trial. We included data from 33 patients with liver malignancies (mean/std 142 of age: 62.91/12.34 year; 16 male, 17 female). dMRI was based on diffusion-weighted 143 (DW) echo planar imaging (EPI) scans performed with clinical systems, namely: Twice-144 145 Refocussed Spin Echo (TRSE) DW-EPI on a 1.5T Siemens Prisma system; PGSE DW-EPI on a 3T GE SIGNA Pioneer system. We also obtained digitised HE-stained images, from 146

biopsies taken from one of the liver tumours. Biopsies were available for 18 patients, and 147 148 were collected at baseline, immediately after dMRI (before starting immunotherapy). Of the 33 patients, clinical outcome was available for 30 patients, who effectively entered the 149 immunotherapy trial after screening. For 15 of them, a biopsy was also available. The 150 outcome was in the form of standard progression-free survival (PFS). 151

We used coupled dMRI-histology to design an optimal dMRI signal model (N = 25), while 153 coupled dMRI-clinical outcome for a clinical demonstration (immunotherapy response 154 assessment, N = 30), as illustrated in Fig. 1. 155



152



157 158

Fig. 1. Illustration of the liver MRI and histology data used in the study. Our data set consisted of preclinical and clinical data. The preclinical data encompasses dMRI scans of 159 seven fixed livers from mice (six implanted with tissue from biopsies of patients suffering 160 from prostate cancer; one without any implantation). We scanned the livers ex vivo on a 161 9.4T system, and obtained HE histological sections at known position. The clinical data 162 includes in vivo liver dMRI scans performed on 33 patients suffering from advanced liver 163 tumours. Scans were performed on clinical 1.5T and 3T MRI systems. For 18 patients, HE-164 stained material from a biopsy taken from one of the imaged liver tumours was also 165 available. 30 out of 33 patients effectively participated in a phase I immunotherapy trial, 166 and clinical outcome was available as PFS. We used a total sample size of N = 25 for dMRI 167 model design and of N = 30 for response assessment. In the figure, PC standard fort prostate 168 cancer and HCC for hepatocellular carcinoma. 169

Overview: dMRI signal models 170

We continue by presenting the different liver dMRI biophysical models examined in this 171 article. All models account for restricted diffusion inside spherical cells and hindered 172 diffusion in the extra-cellular space – a common modelling framework in body dMRI (6, 173 174 19, 22). Models can be grouped into two families (Fig. 2.A; see Material and Methods for 175 implementation details).

The first family of models is more general, in that it does not make any assumption on which is higher between intra-cellular and extra-cellular ADC (referred to as ADC_I and ADC_E from now on). It includes the following models:

- i. *Diff-in-exTD*: it accounts for restricted intra-cellular diffusion within spheres, modelling cells (6), and hindered diffusion in the extra-cellular space, with diffusion time dependence (TD) (27) in both intra-cellular and extra-cellular spaces (28). Note that the diffusion time is describes for how long water molecules can sense cellular barriers before the MR image is acquired.
- ii. *Diff-in-ex*: as previous model *Diff-in-exTD*, but neglecting TD in the extra-cellular space. Popular techniques such as IMPULSED (19) or VERDICT (20) are practical implementations of this model, with intra-/extra-cellular diffusivities fixed to *ad hoc* values.

Conversely, the second family of models explicitly assumes that $ADC_E > ADC_I$, and assumption made in related dMRI techniques (e.g., Restriction Spectrum Imaging in the prostate (29); power-law axon radius mapping in the brain (7)). This family includes:

- i. Diff-in-exTDFast: equivalent to Diff-in-exTD but ensuring that $ADC_E > ADC_I$.
- ii. Diff-in-exFast: equivalent to Diff-in-ex but again ensuring that $ADC_E > ADC_I$.
- iii. *Diff-in*: a model where it is hypothesised that the signal is dominated by intracellular water contributions (or, in other words, that the extra-cellular signal is negligible due to fast diffusion).

Overview: dMRI metrics

We fitted all models to the dMRI data, obtaining voxel-wise estimates of key tissue parameters, namely: *volume-weighted mean cell size* (vCS_{MRI} , expressed in µm) and *intracellular signal fraction* (F_{MRI} , dimensionless). We combined those two into a surrogate metric of *cell density per unit volume* ($CD_{MRI} = F_{MRI}/vCS_{MRI}^3$, expressed in cell mm⁻³), as shown in other studies (20). For reference, we benchmarked our dMRI metrics against routine ADC (in µm² ms⁻¹) and apparent diffusion excess kurtosis *K* (dimensionless) from diffusion kurtosis imaging (DKI) (30). These are popular dMRI indices sensitive to cancer cellularity, which can be computed from short dMRI acquisitions (20, 31). The details of the fitting procedures can be found in the Materials and Methods.

We processed HE-stained histological data with automatic cell detection (32) to derive histological counterparts of vCS_{MRI} and F_{MRI} at known radiographic location (details in the Materials and Methods section). The histological metrics were: histological volumeweighted mean cell size (vCS_{histo} , in µm), intra-cellular area fraction (F_{histo} , dimensionless), and cell density per unit area (CD_{histo} , in cell mm⁻²). The direct comparison between vCS_{MRI} and vCS_{histo} and between F_{MRI} and F_{histo} enables histology-informed dMRI model selection (Fig. 2B).

218

177

178

179

180

181

182

183

184

185

186

187

188 189

190

191

192

193

194

195

196

197 198 199

200 201

202

203


204

205

206

207

208



220 221 222 223 224 225 226 227 228 229 230

219

Fig. 2. Description of the dMRI signal models and study overview. (A), top: cartoon illustrating the two families of dMRI models considered in this study, consisting of 1) models with no assumption of which of intra/extra-cellular ADC is higher, and 2) models where the extra-cellular ADC is hypothesised to be higher than the intra-cellular ADC. (**B**), bottom: study overview. We analysed dMRI data from fixed mouse livers (preclinical data) and from cancer patients imaged in vivo (clinical data) to derive estimates of intra-cellular fraction and of cell size. In parallel, we processed histological material from the same tissues (whole-liver sections for the preclinical mouse data; biopsies from one of the imaged tumours for the clinical data), and derived the histological counterparts of such dMRI metrics. We compared dMRI and histological cell size and intra-cellular fraction to select the dMRI model featuring the best fidelity to histology. The utility of the model was then demonstrated in immunotherapy response assessment in vivo. In Fig. 2, pictures from 231 Servier Medical Art have been used. Servier Medical Art by Servier is licensed under a 232 Creative Commons Attribution 3.0Unported 233 License 234 (https://creativecommons.org/licenses/by/3.0).

- 235
- 236

239

240

241

242


243

244

245 246

A one-pool model of intra-cellular diffusion provides the most histologically 237 meaningful metrics 238

Fig. 3A summarises the different dMRI models, while Fig. 3B reports values of the MRI-Histology Total Correlation Score (TCS) for all models. TCS measures the overall correlation between histological and radiological readouts of cell size and intra-cellular fraction. It was computed by summing Pearson's correlation coefficients between vCS_{MRI} and F_{MRI} with their respective histological counterparts vCS_{histo} and F_{histo} (see Materials and Methods). Higher values of TCS point towards stronger histological-radiological correlation. Negative correlations reduce TCS, so they are penalised.



247 Fig. 3. Biophysical dMRI signal model selection based on the MRI-histology Total 248 Correlation Score (TCS). (A): panel summarising the salient differences between the 249 biophysical dMRI models compared in this study. Models can be divided in two families, 250 i.e.: i) models where it is hypothesised that the extra-cellular ADC is higher than the intra-251 cellular ADC, and ii) models with no hypothesis on which, between intra-/extra-cellular 252 ADC is higher. Violet shades are used for the first family (models *Diff-in*, *Diff-in-exFast*) 253 and *Diff-in-exTDFast*), while orange shades for the second family (models *Diff-in-ex* and 254 *Diff-in-exTD*). (B): values of TCS for all models, as obtained by fitting them on high b-255 value images (b > 1800 s/mm² in the fixed mouse livers; b > 900 s/mm² in vivo). We 256 performed model selection using a sample size of N = 25 (see Fig. 1). In Fig. 3, pictures 257 from Servier Medical Art have been used. Servier Medical Art by Servier is licensed under 258 Creative Commons Attribution 3.0 Unported License 259 а (https://creativecommons.org/licenses/by/3.0). 260

The bar plot in Fig. 3B highlights that dMRI models in which that extra-cellular ADC is 261 higher than the intra-cellular one $(ADC_E > ADC_I)$, shown in violet shades, provide 262 consistently higher TCS values than models that do not make such an assumption (orange 263 shades). All models assuming fast extra-cellular diffusion provide similar TCS. However, 264 we observe the highest TCS for model Diff-in. Diff-in is, in practice, a compact 265 representation where the extra-cellular DW signal is neglected compared to the intra-266

cellular one, due to the much faster diffusion occurring in the former. In other words, *Diff-in* assumes that the DW signal can be described as dominated by intra-cellular water, characterised by diffusion restriction within cells of spherical shape. Note that Fig. 3 refers to TCS values obtained by fitting dMRI models only to hih b-value images (see Materials and Methods), as this provided the highest TCS figures. Fig. S2 reports TCS for model fitting performed to the whole set of diffusion images. In this case, TCS is lower, and again, models where $ADC_E > ADC_I$ provide higher TCS than models that do not make this assumption. In Fig. S2, we observe the highest TCS for model *Diff-in-exFast*.

Fig. S3 reports rankings according to additional model selection criteria. These were: the 276 Histology Fidelity Criterion (HFC), measuring the sum of absolute errors in histological 277 intra-cellular fraction F and cell size vCS estimation via MRI, and the Bayesian Information 278 Criterion (BIC). BIC (33), commonly used in dMRI model development (34, 35), quantifies 279 the overall model fitting quality (penalizing model complexity), without accounting for 280 histological information. Lower HFC, as well as lower BIC, imply better model 281 performance. Fig. S3 reports the number of times, in percentage term, that a model provides 282 the overall lowest HFC and BIC across our sample of N = 25 MRI-histology cases. Results 283 essentially confirm rankings seen on TCS: models hypothesising $ADC_F > ADC_I$ are 284 selected more frequently than models that do not do, according to HFC. The model Diff-in 285 is the most selected model according to both BIC and HFC (fig. S3.B; fitting to high b-value 286 images). Fig. S4 splits HFC and BIC rankings depending on the MRI scanner (9.4T for ex 287 vivo mouse liver imaging; 1.5T or 3T for in vivo clinical imaging). In all cases, models with 288 $ADC_E > ADC_I$ (*Diff-in, Diff-in-exFast, Diff-in-exFastTD*) are selected more frequently than 289 models Diff-in-ex and Diff-in-ex-TD. When fitting is performed only on high b-value 290 images, Diff-in is again the most selected model according to both BIC and HFC in all cases. 291 Data S1 reports all TCS, HFC and BIC rankings for the complete set of MRI-histology 292 293 observations.

Computer simulations confirm model selection from actual MRI measurements

We performed Monte Carlo computer simulations to corroborate the model selection 296 297 performed on ex vivo and in vivo dMRI data. The simulations consisted in generating synthetic dMRI signals according to the protocols implemented in the three MRI scanners 298 used in this study. We synthesised signals for a substrate made of packed spherical cells 299 (Fig. S5), a common geometric tissue model used for body dMRI imaging (6, 19, 22, 23), 300 and performed model selection on such syntethic signals as illustrated above (additional 301 details in the Materials and Methods). Supplementary Tables S1, S2, and S3 report TCS, 302 303 HFC and BIC rankings obtained on simulated MRI signals. Results confirm that model Diffin enables the best estimation of cell size and intra-cellular fraction among the candidate 304 models in the majorities of cases, thus confirming results from ex vivo and in vivo MRI. 305

306 307

294

295

267 268

269

270

271

272

273 274

275

308Our proposed approach: fitting of a one-compartment model of intra-cellular309diffusion to high b-value images

In view of all model rankings reported above for *ex vivo*, *in vivo* and synthetic dMRI signals, we propose to *fit a one-compartment model of restricted intra-cellular diffusion within spherical cells to high b-values images* ($\geq 1800 \text{ s/mm}^2 ex vivo$, $\geq 900 \text{ s/mm}^2 in vivo$). This model, referred to as *Diff-in* in this article, is hence our recommended implementation.

314315

316

Cell size and density estimates from the proposed dMRI model correlate with histology

In the following, we report on the Pearson's correlation coefficient *r* between metrics from the proposed *Diff-in* model with their direct histological counterparts. We consider correlations to be weak, moderate, and strong when |r| < 0.4, $|r| \ge 0.4$ but |r| < 0.6, and | $r \ge 0.6$ respectively.

Table 1 reports r between metrics from the proposed model *Diff-in* with their histological 322 counterparts. For reference, we also report correlation coefficients between more standard 323 DKI metrics ADC and K. The correlation between Diff-in metrics F_{MRI} (intra-cellular 324 325 fraction), vCS_{MRI} (cell size index) and CD_{MRI} (cell density) with their counterparts F_{histo} , vCS_{histo} and CD_{histo} are respectively weak (r = 0.19 between F_{MRI} and F_{histo}), moderate 326 $(r = 0.44 \text{ between } vCS_{MRI} \text{ and } vCS_{histo})$ and strong $(r = 0.70 \text{ between } CD_{MRI} \text{ and } CD_{histo})$. 327 The weak correlation between F_{MRI} and F_{histo} can be explained, at least in part, with the 328 329 fact that F_{MRI} is a signal fraction, rather than an actual volume/area fraction (unlike F_{histo}), i.e., it is influenced by T2/T1 differences between intra-cellular and residual extra-cellular 330 signals (36). Moreover, F_{MRI} estimation can be biased by unaccounted exchange between 331 intra-cellular and extra-cellular water (21, 37), a biophysical characteristic that is not 332 accounted for in our signal models. Conversely, the much higher correlations between 333 vCS_{MRI} and vCS_{histo} and between CD_{MRI} and CD_{histo} suggest that vCS_{MRI} and CD_{histo} 334 may be biologically-specific tools to monitor the cytoarchitecture of the liver in vivo. 335

Table 1 also reports correlation coefficients between standard dMRI ADC and kurtosis K 337 with histological F_{histo} , vCS_{histo} and CD_{histo} . Both ADC and K exhibit significant, 338 moderate correlations with histological properties. For example, negative/positive 339 correlation of ADC/K with cell density CD_{histo} (r = -0.47 and 0.43 respectively) are seen 340 - a result entirely consistent with previous studies (38, 39). Significant correlations are also 341 seen with F_{histo} (r = 0.40, p = 0.048 between K and F_{histo}), again in line with known 342 343 literature: ADC and K are sensitive to the underlying tissue microstructure. Nevertheless, 344 they are also unspecific, being surrogate metrics difficult to interpret, which conflate different histopathological characteristics into a single number. 345

Fig. S6 and Fig. S7 show Pearson's correlation coefficients for all possible paird of metrics, 347 in the form of correlation matrices. The figures report correlations for all models and all 348 349 fitting strategies (fitting to the whole set of dMRI images, or only to those acquired at high b-value). Correlations among dMRI metrics are seen, as for example a strong negative 350 correlation between CD_{MRI} and νCS_{MRI} (r = -0.84 for model *Diff-in-exFast* fitted at high b-351 value). This finding, which indicates that tighter cell packings per unit volume are achieved 352 with smaller cells, is biophysically plausible, being mirrored by histological CD_{histo} and 353 νCS_{histo} (r = -0.88 between CD_{histo} and νCS_{histo}). Other weak-to-moderate correlations 354 are seen, e.g., between K and vCS_{MRI} (r = -0.47) and CD_{MRI} (r = 0.38), which agree with 355 the correlations observed between K and histological νCS_{histo} (r = -0.31) and CD_{histo} (r = 356 357 0.43). In general, metrics from dMRI models where $ADC_E > ADC_I$ (models Diff-inexTDFast, Diff-in-exFast, Diff-in) show stronger correlations with their histological 358 359 counterparts, as compared to models without such an assumption (Diff-in-exTD and Diff-inex). We observe the strongest dMRI-histology correlations for model *Diff-in* fitted to high 360 b-value images. Fitting models to high b-values images provides stronger dMRI-histology 361 correlations in all cases for models where $ADC_E > ADC_I$ (*Diff-in-exTDFast*, *Diff-in-exFast*, 362 363 *Diff-in*), while it does not necessarily do for the other models (*Diff-in-exTD* and *Diff-in-ex*).

364 365

321

336

346

367

369

370

371

372

373

374

375

376 377

368

Table 1. Correlation between dMRI metrics and histological metrics. The table reports Pearson's correlation coefficients r and corresponding p-values p of dMRI metrics F_{MRI} (intra-cellular fraction), vCS_{MRI} (volume-weighted cell size index) and CD_{MRI} (cell density per unit volume) with their histological pairs (F_{histo} , νCS_{histo} and CD_{histo} respectively) for the selected dMRI model (Diff-in, fitted to high b-value images). The table also reports correlation coefficients between routine ADC and K from DKI and each of Fhisto, vCShisto and CD_{histo} . The sample size was N = 25, so that that p < 0.05 if |r| > 0.3961. When p < 0.050.05, grey shadowing is used.

dMRI technique	Histology F _{histo}	Histology vCS _{histo}	Histology CD _{histo}
Model	With F_{MRI} :	With vCS_{MRI} :	With <i>CD_{MRI}</i> :
Diff-in	r = 0.19; p = 0.37	r = 0.44; p = 0.029	r = 0.70; p = 0.0001
	With ADC:	With ADC:	With ADC:
Routine	r = -0.28; p = 0.18	r = 0.49; p = 0.014	r = -0.47; p = 0.017
DKI	With <i>K</i> :	With <i>K</i> :	With <i>K</i> :
	r = 0.40; p = 0.048	r = -0.31; p = 0.13	r = 0.43; p = 0.033

378

379

380

381

382

383

384

Metrics from the proposed dMRI model reveal intra-/inter-tumour characteristics

Fig. 4 shows maps from the proposed dMRI model *Diff-in*, as well as corresponding histological metrics in 3 mouse livers. These are representative of the 3 histopathological phenotypes seen in our mouse data, namely: sample Control, for normal liver structures; sample *Patinfl*, for generalised small cell infiltration; sample *Patnec*, for necrosis.

385 Fig. 4 shows excellent co-localisation between MRI slices and histology sections. The 386 histological details reveal the higher cellularity of sample Patinfl compared to Control, due 387 388 to packing of small cells in between larger hepatocytes. They also show that sample Patnec features an alternation of areas with extremely low cell density (i.e., necrosis), with areas 389 with higher abundance of cells. These qualitative trends are confirmed in the histological 390 maps F_{histo} , vCS_{histo} , CD_{histo} : Pat_{infl} exhibits the highest F_{histo} and CD_{histo} as well as 391 lowest vCS_{histo} of all samples; Pat_{nec} shows a patchy structure, with locally-low F_{histo} and 392 CD_{histo}, indicating necrosis. Control sample maps are in physiologically plausible ranges, 393 as for example intra-cellular fractions around 0.75 and cell sizes of the order of 25 μ m (40, 394 41). Maps F_{MRI} , vCS_{MRI} and CD_{MRI} replicate the contrasts seeing in their histological 395 counterparts F_{histo}, vCS_{histo} and CD_{histo}. Fig. S8 shows standard dMRI metrics, namely 396 ADC and kurtosis excess K, in the same mouse livers. Visual trends highlight that the higher 397 cell density of sample Pat_{infl} translated to remarkably reduced ADC and increased K 398 compared to the *Control*, is in line with known correlations with cellularity (38, 39). Lastly, 399 Fig. S9 shows F_{MRI} , vCS_{MRI} and CD_{MRI} maps from another model (*Diff-in-exFast*, 400 providing the highest TCS for fitting performed to the whole set of images). Fig. S10 instead 401 shows maps of the other metrics provided by models Diff-in-exFast and Diff-in (intrinsic 402 cytosol diffusivity $D_{0,I}$ and asymptotic ADC_E , $D_{E,\infty}$). The figures highlight that overall, 403 spatial trends seen in maps from the selected model Diff-in agree with those seen in Diff-in-404 *exFast.* Metrics $D_{0,I}$ and $D_{E,\infty}$ show limited between-sample contrast, and are difficult to 405 validate histologically. 406 407

Table S4 and Data S2 report qualitative per-sample mean and standard deviation of all MRI and histology metrics, highlighting that F_{MRI} slightly underestimates F_{histo} , while vCS_{MRI} slightly overestimates the numerical value of vCS_{histo} . We speculate that the discrepancies may be due, at least in part, to unaccounted factors such as variability in intrinsic cell shape/cytosol diffusivity (42) or water exchange (21), and by the intrinsic challenge of relating histology metrics derived from 2D data to 3D MRI (43).




408


409

410

411

412





424 fraction F_{histo} ; volume-weighted mean cell size index νCS_{histo} ; cell density per unit patch 425 area CD_{histo}). (**D**), *bottom right*: dMRI maps F_{MRI} , νCS_{MRI} and CD_{MRI} from the selected 426 dMRI signal model (model *Diff-in*, fitted to high *b*-value images, i.e., b > 1800 s/mm²;).

Fig. 5 shows F_{MRI} , vCS_{MRI} and CD_{MRI} maps in patients, alongside biopsies. Assessment of 428 histopathology highlights the variety of characteristics that can coexist within advanced 429 solid tumours, e.g.: areas of fibrosis; areas with tightly packed cancer cells embedded within 430 stromal scaffolding; extensive areas of necrosis. Notably, dMRI maps F_{MRI} , vCS_{MRI} , CD_{MRI} 431 show contrasts that are plausible with the histopathological features seen on the biopsies, as 432 for example: a core of low intra-cellular fraction F_{MRI} and low cell density CD_{MRI} in a breast 433 cancer case, corresponding to necrosis; local areas of high F_{MRI} and low νCS_{MRI} in the 434 HCCs, indicative of tightly packed cancer cells. Fig. S11 shows routine dMRI ADC and K 435 in the same tumours. ADC and K trends are compatible with the histology seen on the 436 biopsies, e.g., a core of high ADC and low K in the necrotic core of the BC tumour. 437 Supplementary Fig. S12 shows F_{MRI} , vCS_{MRI} and CD_{MRI} from model *Diff-in-exFast*. Image 438 contrasts match visually those seen in the same metrics from model Diff-in (the proposed 439 approach), giving confidence of the overall robustness of the biophysical modelling 440 framework. Fig. S13 shows intra-cellular cytosol diffusivity $D_{0,I}$ asymptotic $ADC_E(D_{E,\infty})$ 441 in the same tumours. Their speckled appearance suggests that these metrics are difficult to 442 measure accurately in vivo (19, 44). 443




Fig. 5. Examples of maps from the proposed dMRI model *Diff-in* in liver tumours of patients scanned at 1.5T and 3T *in vivo*, with co-localised biopsies. MRI maps are shown in a biopsied liver tumour in two patients for each MRI scanner, arranged along rows. (A): examples of slices from the high-resolution anatomical T2-w image and from a high b-value image, with biopsied tumour outlined. (C): maps from the selected model (*Diff-in*, fitted to high b-value images b > 900 s/mm²). From left to right: intra-cellular signal fraction F_{MRI}; volume-weighted mean cell size index vCS_{MRI}; cell density per unit volume CD_{MRI}. (C): histological details from the HE-stained biopsy. For the 1.5T Siemens scanner (first and

446 447 448

445

427

- 449
- 450
- 451

second rows from top) we report: patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (third and fourth rows from top) we report: patient 24 (primary hepatocellular carcinoma (HCC)) and patient 30 (liver metastases from breast cancer).

457 458 459

454 455

456

460 Metrics from the proposed dMRI model stratify the risk of cancer progression in 461 immunotherapy


Finally, we demonstrate the potential utility of the proposed liver dMRI model in an exemplificatory response assessment task in immunotherapy. This consisted of stratifying the risk of cancer progression, given baseline values of dMRI metrics within liver tumours obtained immediately prior to treatment.

466

Fig. 6 reports response assessment based on metrics from the proposed model Diff-in, 467 (intra-cellular fraction F, volume-weighted cell size index vCS, and cell density per unit 468 volume CD). Panels on the left report results from Kaplan-Meier analysis, log-rank testing 469 and Cox regression performed after binarising dMRI metrics as higher/lower than the 470 median of the cohort. Panels on the right report instead results from Cox regressions 471 assessing the continuous dependence of PFS on F, vCS and CD. We do not observe any 472 statistically significant associations between baseline F_{MRI} and probability of progression. 473 Conversely, we detect a dependence of the probability of progression on baseline vCS_{MRI} 474 and CD_{MRI} . The Kaplan-Meier curves of the two groups differ significantly for both vCS_{MRI} 475 (log-rank test: p = 0.047, Fig. 6C) and CD_{MRI} (log-rank test: p = 0.035, Fig. 6E). These 476 differences correspond to statistically significant Hazard Ratios (HRs) from Cox regression 477 (HR = 0.47, p = 0.050 for binarised vCS_{MRI} ; HR = 2.36, p = 0.043 for binarised CD_{MRI}). 478 479 These findings suggest that smaller values of cell size νCS_{MRI} or, alternatively, higher values of cell density CD_{MRI} within liver tumours at baseline, may be indicative of faster 480 progression risk under immunotherapy. In practical terms, the risk of progression is about 481 twice as high in patients whose baseline cell size vCS_{MRI} is smaller than the median vCS_{MRI} , 482 compared to patients where it is larger. Similarly, the risk of progression is about twice as 483 high in patients whose baseline cell density CD_{MRI} is higher than the median CD_{MRI} , 484 compared to those where it is lower. Importantly, we found similar associations between 485 the risk of progression and baseline vCS_{MRI} and CD_{MRI} when these two metrics are not 486 binarised, but rather used as continuous predictors in Cox regression (right panels in Figure 487 6). In this latter case, the HR was statistically significant for νCS_{MRI} (HR = 0.65, p = 0.034, 488 Fig. 6D), and it approached statistical significance for CD_{MRI} (HR = 1.40, p = 0.055, Fig. 489 6F). Noteworthily, these association are not confounded by age, sex or baseline tumour 490 volume (Supplementary Table S5; HR = 0.59, p = 0.02 for vCS_{MRI} ; HR = 1.65, p = 0.01 for 491 492 CD_{MRI}). 493

Fig. 7 and supplementary Fig. S14, Fig. S15 and Fig. S16 report results for the response 494 assessment based on all other dMRI metrics considered in this study (e.g., routine ADC and 495 K in Fig. 7; cytosol diffusivity $D_{0,I}$ for model *Diff-in* in Fig. S14; vascular fraction f_V in Fig. 496 S15; all metrics from model Diff-in-exFast in Fig. S16). While the estimated HRs for 497 metrics vCS_{MRI}, F_{MRI} and CD_{MRI} from dMRI model Diff-in-exFast go in the same direction 498 as those from model *Diff-in*, their association with the probability of progression is weaker, 499 and only reaches borderline statistical significance for CD_{MRI} (HR = 1.53; p = 0.05; Table 500 S5). This finding is likely due to the intrinsic higher variability (and hence, lower statistical 501 power) of metrics from model Diff-in-exFast compared to model Diff-in, since the latter 502 model has one parameter less to estimate, making it easier to fit. Importantly, baseline 503

values of routine *ADC* and *K* do not show any association with the probability of progression (Fig. 7 and Table S5).



508 509 510

511

512

513

514

515

516

517

518

507

Fig. 6. Immunotherapy response assessment based on metrics from the proposed model *Diff-in* within liver tumours at baseline. This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of F, vCS and CD within liver tumours at baseline (i.e., before starting immunotherapy), as obtained by fitting model *Diff-in* at high b-value. *Left*: Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline F (panel A), vCS (panel C) and CD (panel D) (lower/higher than the sample median). The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. *Right*: results from univariate

504

Cox regression where the baseline *F* (panel B), *vCS* (panel D) and *CD* (panel F) is a continuous predictor of the survival. The panel shows how changes in baseline *F*, *vCS* and *CD* modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows 1 - p, with *p* being the probability of progression, while the x-axis shows the time to progression (in days). We performed the response assessment using a sample size of N = 30 (Fig. 1).




 Fig. 7. Immunotherapy response assessment based on mean *ADC* **and kurtosis** *K* **within liver tumours at baseline.** This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of *ADC* and *K* within liver tumours at baseline (i.e., before starting immunotherapy). *Left*: Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline *ADC* (panel A) and *K* (panel C) (lower/higher than the sample median). The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. *Right*: results from univariate Cox regression where the baseline *ADC* (panel B) and *K* (panel D) is a continuous predictor of the survival. The panel shows how changes in baseline *ADC* and *K* modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis

Page 15 of 36

shows 1 - p, with p being the probability of progression, while the x-axis shows the time to progression (in days). We performed the response assessment using a sample size of N = 30 (Fig. 1).

547 **Discussion**

543 544

545 546

565

580

The latest liver dMRI signal models account for two key signal compartments, in that they 548 attempt to disentangle intra-cellular and extra-cellular water contributions (6, 19, 22, 23). 549 550 This powerful approach enables the estimation of innovative tissue property maps, which may become useful biomarkers in oncological applications. However, the clinical 551 deployment of advanced models of this type is hampered by their high number of unknown 552 tissue parameters. Estimating accurately several tissue parameters at once requires large sets 553 of MR images or, potentially, specialised dMRI acquisitions. This makes the use of such 554 models impractical in real-world radiology settings (19, 45), where scan time is limited and 555 where most hospitals only have access to vendor-provided acquisitions. With this unsolved 556 challenge in mind, this paper aims to deliver a practical implementation of a two-557 compartment dMRI signal model, tailored for liver imaging, which is truly feasible in the 558 clinic. Through histology-informed model selection, we design a compact dMRI framework 559 consisting of fitting a one-pool model of restricted intra-cellular diffusion to highly DW 560 images. The framework provides pixel-by-pixel estimates of cell size and density that are 561 correlated with the underlying histology. These metrics outperform well-establish ADC and 562 diffusion kurtosis in patient stratification in immunotherapy, suggesting that they could 563 become useful biomarkers in oncological applications. 564

To find the optimal dMRI signal implementation, we analysed co-localised dMRI and 566 histology data (N = 25). These consisted of: i) MR images and HE sections of fixed mouse 567 livers processed ex vivo, and ii) in vivo dMRI scans of cancer patients and HE-stained 568 biopsies from one of the imaged liver tumours. We compared 5 signal models, each fitted 569 according to two distinct strategies, and ranked them for their ability to accurately estimate 570 intra-cellular fraction and cell size metrics, compared to reference histology. Rankings, 571 confirmed by Monte Carlo computer simulations, unequivocally suggest the highest 572 radiological-histological agreement is obtained by fitting a single-compartment model of 573 diffusion (restricted diffusion within spherical cells – a model here referred to as *Diff-in*) to 574 images acquired with b-values higher than approximately 900 s/mm² in vivo and 1800 575 s/mm² ex vivo. Diff-in, a model whose deployment is feasible in the clinic with scan times 576 of under 15 minutes, and with default dMRI examinations made available by MRI vendors, 577 provides cell size and density estimates that correlate moderately and strongly with 578 histology, and which may therefore become biologically-specific biomarkers. 579

Interestingly, our central result points towards the fact that simpler models of diffusion (e.g., 581 single- vs two-compartment), can provide the highest fidelity to the underlying histology, if 582 deployed in appropriate measurement regimes. This is the case, in our settings, in presence 583 of strong diffusion-weighting, which minimises extra-cellular signal contributions. Notably, 584 our finding partially disagrees with some of the latest trends in body dMRI development. 585 Recent literature has been characterised by the introduction of ever-complex biophysical 586 587 46). While more complex models better capture the true degrees of freedom on *in vivo* dMRI 588 signals, they have the disadvantage of requiring longer and/or more sophisticated 589 acquisition protocols to enable their fitting (26), a fact that negatively impacts on their 590 591 clinical applicability. Conversely, our approach suggests that focussing on measurement regimes where the signal is dominated by intra-cellular diffusion may enable the 592

deployment of simpler models, which still suffice to capture salient features of tissue 593 594 microstructure. This conclusion is in line, for example, to recent modelling approaches seen in brain imaging, which provide axon size indices from dMRI measurements where the 595 extra-axonal signal has been suppressed (7, 47-49). Notably, our model selection results 596 can also be framed within the context of recent literature, since recently extra-cellular liver 597 ADC values as high as 2.5-2.8 μ m² ms⁻¹ have been reported (19). Such a high ADC_F implies 598 that the extra-cellular signal would decay to roughly 5% or less of its non-DW value even 599 for b-values as low as approximately 1200 s/mm² (exp($-b ADC_E$) ≈ 0.05 for b = 1200 s/mm² 600 = 1.2 ms⁻¹ μ m² and ADC_E = 2.5 μ m² ms⁻¹), making the use of a model of intra-cellular 601 diffusion feasible as a proxy for the total DW signal (7), simplifying considerably parameter 602 estimation (44, 50). 603

Importantly, we conducted dMRI model selection using a variety of criteria. These were: 605 the TCS, measuring the overall correlation between dMRI metrics and their histological 606 counterparts; HFC, quantifying the accuracy in estimating histological properties via dMRI; 607 and BIC, a common index of dMRI model quality of fit, which does not take into account 608 any agreement with histology (35). In general, all criteria point towards the same direction, 609 with model Diff-in fitted to high b-value images being the top-ranking model. We would 610 also like to emphasise that the same liver dMRI model implementation (i.e., fitting model 611 *Diff-in* on high b-value images) would have been delivered had we only looked at the ex 612 vivo mouse data, or at in silico signals (Fig. S4, panels A and D). This fact gives confidence 613 on the robustness and generalisability of our dMRI model selection, justifying our choice 614 of using 15 in vivo dMRI scan for both histology-informed model design and for the clinical 615 demonstration in immunotherapy. 616

Another important observation is that two distinct histology-informed model selection 618 criteria, i.e., TCS and HFC, unequivocally suggest that models where the extra-cellular 619 ADC is constrained to be higher than the intra-cellular ADC, outperform more general 620 models. The better performance of these models, compatible with values of extra-cellular 621 ADC of approximately 2.5 μ m² ms⁻¹ reported in (19), is not apparent when looking at BIC 622 rankings (e.g., Fig. S3.A, Fig. S4.A, Fig. S4.B, Fig. S4.C). This minor discrepancy can be 623 understood considering that a good signal fitting quality may not necessary imply accurate 624 parameter estimation, especially in presence of noisy measurements (26). dMRI signal 625 model fitting is a highly degenerate inverse problem, since strikingly different combinations 626 of tissue parameters (and hence, different estimated cytoarchitectures) can provide similar 627 fitting quality (44). This finding stresses the importance of informing dMRI modelling with 628 information from histology, striving for biological specificity. 629

After selecting a practical dMRI model implementation, we investigated its utility in an 631 exemplificatory immunotherapy response assessment task. Immunotherapy treatments, 632 such as immune checkpoint inhibitors, have shown promise in several cancers (16). 633 However, only a small fraction of patients truly benefits from these treatments, and their 634 635 identification prior to drug administration remains an unsolved challenge (17). With this in mind, we investigated on a sample of N = 30 patients whether it is possible to stratify the 636 probability of progression, given baseline values of dMRI metrics within liver tumours. 637 Several, independent statistical analyses consistently point towards the fact that smaller 638 baseline dMRI cell sizes and higher dMRI cell densities, are associated to faster cancer 639 progression under immunotherapy, as measured by PFS. To our knowledge, this is the first 640 641 time that markers of cell size and density, derived non-invasively in patients *in vivo* with dMRI, have been tested in patient stratification in the context of immunotherapy. Notably, 642

604

617

the deleterious impact of higher cell density on clinical outcome is in line with other studies 643 644 focussing on different treatments, where higher tumour cellularity has been associated with higher cancer aggressiveness or worse prognosis. In CRC liver metastasis resection, for 645 example, high cell density in resected metastases has been associated to shorter disease-free 646 survival (51). Conversely, in breast cancer, lower tumour cellularity has been associated to 647 pathologic complete response in chemo-free dual HER2 blockade treatment (for HER2-648 positive BC) (52), as well as longer survivals in neoadjuvant chemotherapy (53). The 649 significant association between immunotherapy PFS and baseline dMRI cell size/density 650 reported here is promising, and motivates future imaging studies. However, we remark that 651 such a finding, while encouraging, comes from an exploratory proof-of-concept 652 demonstration of our biophysical liver dMRI approach in immunotherapy, which requires 653 validation in larger and independent cohorts. 654

In this study, we benchmarked the proposed dMRI approach against well-established DKI 656 apparent diffusion and kurtosis coefficients (ADC and K) (30). ADC and K have shown 657 utility in clinical settings, being easy to compute with compact dMRI acquisitions, and 658 sensitive, for example, to cancer cellularity (negative/positive correlation for ADC/K (46), 659 a result confirmed by the correlations detected in this study, namely: r = -0.47 between 660 ADC and CD_{histo} , r = 0.43 between K and CD_{histo}). However, in our cohort, neither of ADC 661 and K showed statistically significant associations with the clinical outcome (PFS). This 662 may due, at least partly, to the fact that ADC and K are semi-quantitative, protocol-663 dependent metrics, whose value can change as function of, for example, the diffusion time 664 (46, 54). Here, we did not perform any inter-scanner harmonisation delibterately, to stress 665 the quantitative nature of our cell size/density mapping approach, which inherently accounts 666 for inter-scanner protocol differences. However, we acknowledge that better performances 667 for semi-quantitative metrics such as ADC and K could be obtained by incorporating inter-668 scanner harmonisation (55, 56) in the MRI analysis pipeline. 669

We would like to acknowledge the following potential limitations of our study. Firstly, our 671 sample size (N = 25 paired dMRI-histology measurements for model development; N = 30672 paired dMRI-outcome measurements in patients) is relatively small. This paper provides a 673 first demonstration of the potential utility of a single-compartment model of restricted 674 diffusion fitted to high b-value data in the liver. The demonstration is unique of its kind, 675 since it reports, for example, heretofore undescribed dMRI-based stratification in 676 immunotherapy, providing useful reference standards for future biomarker development 677 studies. Moreover, to our knowledge there are no freely available multi b-value liver dMRI 678 data sets with coupled histological and/or clinical information that could serve as 679 independent test beds for our findings. Nonetheless, while works proposing related dMRI 680 techniques relied on similar (23, 36), if not even smaller (19, 20), sample sizes, we 681 acknowledge that our findings are exploratory. Further confirmation is required in diseases 682 beyond liver cancer, treatments other than immunotherapy, as well as from a larger number 683 of dMRI scanners, protocols, and patients. 684

686 Secondly, we acknowledge that results from dMRI-histology comparisons should be always 687 taken with care. For example, here we related dMRI metrics obtained *in vivo* to histological 688 indices from biopsies. While we were able to identify the liver tumours from which the 689 biopsies were taken, we could not identify exactly the area, within a tumour, that was 690 biopsied. This may imply that we may have underestimated the true correlation between 691 dMRI and histological metrics. Also, and most importantly, histology has its own 692 limitations, since it provides cell property estimates that may not be, *per se*, fully accurate.

655

670

For example, routine HE histology is an inherently 2D technique, unlike 3D MRI. 693 Moreover, it is affected by artifacts (e.g., due to dehydration, paraffin embedding, imperfect 694 staining, cutting, etc (57)), and the automatic processing of large histological fields-of-view 695 requires trading off between sensitivity and specificity. We took steps to mitigate these 696 issues, e.g., by accounting for biases due to tissue shrinkage. Nonetheless, we acknowledge 697 that our histology-derived estimates of cell properties may be biased versions of the true 698 figures. However, we find encouraging that the same dMRI models provided the best 699 700 fidelity to histology according to independent rankings (e.g., HFC and TCS criteria), giving confidence on the histological validity of the proposed dMRI approach. 701 702

We would also like to acknowledge that the proposed dMRI approach neglects other 703 potentially relevant microstructural properties, such as mapping of water exchange between 704 the intra-/extra-cellular space (21, 37), full intra-voxel cell size/cytosolic diffusivity 705 distributions (42, 58), or intra-compartmental T2 or T1 (36). One the one hand, this can lead 706 to biases in our estimates of cell size, intra-cellular fraction or cell density. It could also 707 explain, for example, the weak correlation seen between dMRI-derived and histology-708 derived intra-cellular fraction: dMRI intra-cellular fraction estimates have been shown to 709 be biased by unaccounted exchange (21, 37). On the other hand, properties such as exchange 710 rates may be relevant *per se*, as they could be useful markers of cellular stress. However, 711 we would like to remark that increased model complexity may lead to higher overall 712 variability of the estimated tissue parameters, especially when short, clinically feasible 713 dMRI protocols are considered, as done in this study. In future work we aim to incorporate 714 additional tissue properties to our biophysical model implementations, ensuring that these 715 could be deployed reliably in clinical settings. 716

In conclusion, this study delivers a practical liver dMRI signal model consisting of a single-718 compartment of restricted diffusion within spherical cells, which should be fitted to b-values 719 higher than, approximately, 900 s/mm² in vivo. In our data set, this model offers estimates 720 of cell size and cell density that are, respectively, moderately and highly correlated to the 721 underlying histology. Moreover, these metrics may provide complementary information to 722 routine volumetric tumour burden measurements in applications such as immunotherapy, 723 since they enable the stratification of the risk of progression from baseline dMRI scans. 724 Striving to bringing precision imaging one step closer to the clinic, we release our approach 725 as an easy-to-use, open-source Python implementation, which will be freely accessible 726 online. 727

728 729

731

717

730 Materials and Methods

Experimental design

In this study we collected and analysed co-localised liver dMRI and HE-stained histological 732 data to design a practical signal model with high fidelity to histology, and feasible in the 733 clinic. Moreover, we analysed dMRI scans acquired *in vivo* on cancer patients suffering 734 from advanced solid tumours, and participating in a phase I immunotherapy trial. We 735 analysed these scans to assess whether metrics from the proposed dMRI approach enable 736 the stratification of the risk of progression under immunotherapy. In the following sections, 737 we will first introduce the dMRI models object of this paper. Afterwards, we will provide 738 details of the data acquisition and statistical analysis. We will refer to dMRI and histology 739 images acquired in fixed mouse livers ex vivo as preclinical data. We will instead refer to 740 741 data acquired in patients in vivo, encompassing dMRI, biopsies, and clinical information, as clinical data. 742

dMRI models

Common biophysical dMRI signal models used in body applications accounts for three, non-exchanging water pools, namely: vascular water, characterised by incoherent flow (pseudo-diffusion) in fluid-filled conduits; restricted, intra-cellular water; hindered, extra-cellular, extra-vascular water. This general three-pool representation has found application in several tissues and organs, e.g., colorectal cancer xenografts (6), human prostate (20), liver (19) or breast (59). According to this representation, the dMRI signal for a standard PGSE experiment measured at a b-value b, diffusion gradient duration δ , separation Δ , and echo time TE is written as (6, 19, 20, 60)

$$s = s_0 \left(f_V e^{-\frac{TE}{T_{2V}}} a_V + (1 - f_V) \left(f_I e^{-\frac{TE}{T_{2I}}} a_I + (1 - f_I) e^{-\frac{TE}{T_{2E}}} a_E \right) \right). (1)$$

Above, s_0 is the apparent proton density, f_V is the vascular signal voxel fraction, f_I is the intra-cellular signal tissue fraction, $T2_V/T2_I/T2_E$ and $a_V/a_I/a_E$ are the T2 constants and diffusion-weighting factors of the vascular, intra-cellular and extra-cellular signals.

The vascular diffusion-weighting factor a_V captures the intra-voxel incoherent motion (IVIM) effect (*61*), i.e., signal attenuating arising from blood perfusing within intricated networks of capillaries. *In vivo*, the IVIM signal decay occurs at a rate that is considerably higher than that of the intrinsic fluid diffusivity: the vascular ADC has been reported to range in intervals as high as [15; 60] μ m² ms⁻¹ (*62*). For this reason, for sufficiently high b-values (no less than $b > 100 \text{ s/mm}^2$ *in vivo*), the vascular signal vanishes. For example, a_V reduces to approximately 5% of its non-diffusion-weighted value for $b = 150 \text{ s/mm}^2$ and for a vascular ADC of 20 μ m² ms⁻¹, since exp(-150 s mm² × 20 μ m² ms⁻¹) = exp(-0.15 × 20) = 0.0498. In such a measurement regime, Eq. (3) reduces to a two-pool representation (*19*), which will be the starting point of our modelling framework, i.e.,

$$s = s_0 (1 - f_V) \left(f_I e^{-\frac{TE}{T_{2_I}}} a_I + (1 - f_I) e^{-\frac{TE}{T_{2_E}}} a_E \right). (2)$$

A common model for the intra-cellular diffusion-weighting factor a_I in Eq. 4 is that of restricted diffusion within spheres of diameter L (19, 20). In this case, a_I depends on the b-value b, gradient duration δ and gradient separation Δ as

$$a_I = e^{-b ADC_I(\delta, \Delta, D_{0,I}, L)}, \quad (3)$$

where

$$ADC_{I} = \frac{2}{D_{0,I}\delta^{2}(\Delta-\delta/3)} \sum_{m=1}^{\infty} \frac{\alpha_{m}^{-4}}{\alpha_{m}^{2}R^{2}-2} \left(2\delta - \frac{2+e^{-\alpha_{m}^{2}D_{0,I}(\Delta-\delta)}-2e^{-\alpha_{m}^{2}D_{0,I}\delta}-2e^{-\alpha_{m}^{2}D_{0,I}\Delta}+e^{-\alpha_{m}^{2}D_{0,I}(\Delta+\delta)}}{\alpha_{m}^{2}D_{0,I}}\right)$$
(4)

is the Gaussian phase distribution approximation of the intra-cellular ADC (63). Above, α_m is the *m*-th root of $\alpha_m R J'_{3/2}(\alpha_m R) - 0.5 J_{3/2}(\alpha_m R) = 0$, $J_{3/2}(x)$ is the Bessel function of the first kind and order 3/2, and $J'_{3/2}(x)$ its first-order derivative. ADC_I depends on the intrinsic intracellular diffusivity $D_{0,I}$ (i.e., the diffusivity of the cytosol), and on the cell size L = 2R

(with *R* being the cell radius, whereas *L* is the diameter). Note that in practice, large cells contribute substantially more to the total dMRI signal than small cells, since they contain more water and feature stronger diffusion time dependence. For this reason, dMRI estimates of cell size *L* in fact represent volume-weighted mean cell size statistics (7, 42). Therefore, throughout this manuscript, dMRI cell size *L* has been referred to as a *volume-weighted cell size* (*vCS*) index.

Conversely, the extra-cellular, extra-vascular signal may be described in terms of hindered diffusion in a tortuous space (19, 27, 60), i.e.,

$$a_{E}(b,\Delta) = e^{-b ADC_{E}(\Delta,D_{E,\infty},\beta)}.$$
 (5)

A general form of ADC_E depends on the gradient separation Δ via

$$ADC_E(\Delta, D_{E,\infty}, \beta) = D_{E,\infty} + \frac{\beta}{\Delta}, (6)$$

where in Eq. 6 $D_{E,\infty}$ is the asymptotic, long-time value of ADC_E for $\Delta \to \infty$, while β controls the degree of diffusion time dependence (60).

The 5 implementations of the two-compartment model

It is not yet clear to what extent the complete set of extra-cellular and intra-cellular diffusion properties can be resolved jointly with the minimal dMRI encodings that are feasible in the clinic (19, 27, 44). Here we investigated 5 different practical implementations of Eq. 2, with different levels of detail and complexity. The 5 implementations can be divided into two families, namely: models in which there are no assumptions on which of ADC_I and ADC_E is higher; models hypothesising that $ADC_E > ADC_I$, an assumption compatible, for example, with the values of ADC_E as high as approximately 2.5–2.8 µm² ms⁻¹ measured *in vivo* in the liver in recent studies (19).

The first family of models is more general, and includes two implementations:

- i. *Diff-in-exTD*: the most general implementation, as it accounts explicitly for diffusion TD in the extra-cellular space. It relies on the full expression of ADC_E in Eq. 6, and the search range for $D_{E,\infty}$ is large enough to include values for which ADC_E can either be larger or smaller than ADC_I .
- ii. *Diff-in-ex*: a slightly simpler implementation where extra-cellular TD is considered negligible, i.e., such that $\beta = 0$ in Eq. 6. Again, the search range for $D_{E,\infty}$ is large enough to include values for which ADC_E can either be larger or smaller than ADC_I .

The second family of models, where $ADC_E > ADC_I$, includes 3 implementations:

- i. *Diff-in-exTDFast*: equivalent to *Diff-in-exTD*, but such that the lower bound for $D_{E,\infty}$ ensures that that $ADC_E > ADC_I$ even for the largest cell size L.
- ii. *Diff-in-exFast*: equivalent to *Diff-in-ex*, but again such that the lower bound for $D_{E,\infty}$ ensures that $ADC_E > ADC_I$ for any cell size *L*.
- 831 iii. *Diff-in*: a model where the extra-cellular signal is assumed to be negligible compared 832 to the intra-cellular one, due to ADC_E being much larger than ADC_I . In this 833 implementation we assume that $f_Ia_I + (1 - f_I)a_E \approx f_Ia_I$ for physiological 834 meaningful intra-cellular signal fractions f_I , implying that Eq. 2 reduces to

s =
$$s_0 (1 - f_V) f_I e^{-\frac{TE}{T_2}} a_I(b, \delta, \Delta, D_{0,I}, L).$$
 (7)

For the practical implementation of the 5 dMRI models described above, we assumed that $T2_I \approx T2_E \doteq T2_T$, given the challenge of resolving accurately multiple T2 constants with minimal TE samplings (20, 36), jointly with diffusion properties.

Fitting strategy

836 837

841

842

855

856

861

867

868

We fitted the 5 models custom-written Python routines, based on objective function 843 minimisation initialised by a grid search. The objective function f_{obi} was defined as f_{obi} = 844 $-ln(\lambda)$, where λ is the offset-Gaussian likelihood function, as in (34). Fitting was 845 performed twice. The first fitting was performed on the set of DW measurements where the 846 vascular signal can be considered suppressed, supporting the use of the two-pool 847 representation of Eq. 2. For the sake of simplicity, we will refer to this fitting as "*fitting to* 848 the whole image set", although in practice we mean the whole set of images for which 849 850 vascular contributions can be neglected. Afterwards, we repeated the fitting on a high bvalue subset of the former data set, in which contributions from extra-cellular signals are 851 also minimised. For practical model fitting, we fixed f_V and $T2_I$ to pre-computed values, 852 obtained by fitting a separate diffusion-relaxation model disentangling vascular vs non-853 vascular (i.e., tissue) signals (64). 854

Fitting provided voxel-wise estimates of vCS (vCS = L), as well as the intra-cellular voxel signal fraction *F*, defined as

$$F = (1 - f_V) f_I.$$
 (8)

We combined νCS and F to derive a cell density per unit volume, borrowed from previous literature (20), and defined as

$$CD = \frac{F}{\nu CS^3}.$$
 (9)

Preclinical data

<u>Animals</u>

We obtained data from 7 fixed livers of NOD.Cg-Prkdcscid IL2rgtm1WjI/SzJ mice. All 869 experimental protocols were approved and monitored by the Vall d'Hebron Institute of 870 871 Research Animal Experimentation Ethics Committee (CEEA; registration number 68/20) 872 in accordance with relevant local and EU regulations. We studied six livers from mice implanted with cells derived from biopsies of prostate cancer patients, as part of an ongoing 873 study aiming to develop patient-derived xenografts models, plus an additional liver from a 874 875 mouse without any implantation. We implanted one tumor biopsy core with growth factorenriched Matrigel (Corning) subcutaneously in the flank of each mice. We derived tissue 876 from the following biopsies: iliac bone metastasis biopsy of a patient with metastatic 877 castration-resistant prostate cancer, presenting with bone metastasis and Gleason score 3+4 878 adenocarcinoma; prostate biopsy of a patient with metastatic hormone-sensitive prostate 879 cancer, presenting with bone metastasis and Gleason score 5+4 adenocarcinoma; liver 880 881 biopsy of a patient with metastatic castration-resistant prostate cancer, presenting with bone and visceral metastasis and Gleason score 4+4 acinar adenocarcinoma; liver biopsy of a 882 patient with metastatic hormone-sensitive prostate cancer, presenting with bone and liver 883 metastasis and Gleason score 4+4 adenocarcinoma. After implantation, we measured 884

Page 22 of 36

tumour size using calipers, and monitored mouse weight weekly. We sacrificed animals by cervical dislocation under general anesthesia when tumour volume exceeded 2000 mm³. We collected the livers and fixed them overnight in formalin. Finally, we transferred them to phosphate-buffered saline (PBS) solution for downstream MRI acquisition.

<u>MRI</u>

885

886

887

888 889 890

906

918

The mouse livers were washed in PBS solution for 24 hours and scanned immersed in PBS 891 892 on a 9.4T Bruker Avance system with 200 mT/m gradient inserts at room temperature. Samples were tightened with sewing thread to a histology cassette, which was then placed 893 into a Falcon[®] tube filled with PBS. A 1-channel birdcage coil was used for both excitation 894 and signal detection. The protocol included a high-resolution, anatomical T2-weighted 895 RARE fast spin echo sequence with parameters: TR = 2500 ms; TE = 12 ms; resolution: 896 144 μ m × 144 μ m; matrix size: 230 × 230; 4 slices, 2.216 mm-thick; NEX = 4; RARE factor: 897 8. We acquired dMRI using the vendor's PGSE (Fig. S17A) sequence (TR = 2700 ms; 898 resolution: $386 \text{ }\mu\text{m} \times 386 \text{ }\mu\text{m}$; matrix size: 86×86 ; 4 slices, 2.216 mm-thick, 2 of which 899 containing the liver, NEX = 1). The protocol featured: $\delta = 10$ ms, $\Delta = \{15, 30\}$ ms, 10 900 linearly spaced b-values for each Δ (minimum/maximum b of 0 and roughly 2800 s/mm²). 901 DW images corresponding to $\Delta = 15$ ms were acquired at each of TE = {31, 45, 65} ms, 902 while DW images corresponding to $\Delta = 30$ ms at each of TE = {45, 65} ms. The b-value as 903 a function of the gradient strength G and of δ and Δ can be calculated with the well-known 904 expression $b = \gamma^2 G^2 \delta^2 (\Delta - \delta/3)$. 905

We post-processed dMRI scans as follows. Firstly, we merged all DW images and denoised 907 them with the freely available Python implementation of Marchenko-Pastur Principal 908 Component Analysis (MP-PCA) (65) (kernel size: 7×7×3). Afterwards, we mitigated Gibbs 909 ringing with the local sub-voxel shift method (66) based on MrTrix3, and corrected 910 temporal signal drifts by assessing changes of signal level in a small region of PBS, while 911 accounting for TE changes (T2 of PBS solution: 500 ms). Finally, we fitted the 5 dMRI 912 models (Diff-in-exTD, Diff-in-exTDFast, Diff-in-ex, Diff-in-exFast and Diff-in) voxel-by 913 voxel. Fitting bounds for tissue parameters were: [0; 1] for f_I ; [0.8; 2.6] μ m² ms⁻¹ for $D_{0,I}$; 914 [8; 40] μ m for the vCS parameter L; [0.8; 2.6] μ m² ms⁻¹ for $D_{E,\infty}$ in models Diff-in-ex and 915 Diff-in-exTD, and [1.75; 2.6] μ m² ms⁻¹ in models Diff-in-exFast and Diff-in-exTDFast; [0; 916 10] μ m² for β in models *Diff-in-ex-TD* and *Diff-in-exTDFast*. 917

919 For practical fitting, we fixed f_V and $T2_T$ in each voxel to values obtained by fitting a twopool model disentangling vascular vs tissue signals (64) (fitting bounds: [0; 1] for f_V ; [5; 920 80] ms for $T2_T$). Fitting was performed twice: once, on all images with $b > 1000 \text{ s/mm}^2$ 921 922 (fitting on whole image set); afterwards, for b > 1000 s/mm² (high b-value fitting). In our 923 ex vivo preclinical data, the vascular signal captures partial volume effects with the PBS solution, e.g., at the PBS-liver interface or in large vessels, filled with the liquid, due to lack 924 of blood flow and pulsation. Note that in our ex vivo data, the vascular ADC represents the 925 926 ADC of PBS solution (i.e., free water) at room temperature (fitting bounds: [2.2; 2.8] μm^2 ms^{-1}), hence much smaller than the IVIM-dominated vascular ADC of *in vivo* imaging. For 927 this reason, we adopted a b-value threshold of 1000 s/mm² to achieve a satisfactory 928 suppression of the PBS signal, while we used a minimum b-value of 1800 s/mm² for fitting 929 on high b-value images, minimising the contribution of extra-cellular water. 930

931 932

934

For reference, we also used in-house Python routines to compute standard ADC and apparent diffusion excess kurtosis *K*, by fitting

D 00

$$s = s_0 e^{-b ADC + \frac{1}{6}K(b ADC)^2}$$
 (10)

937 to the set of DW images acquired at TE = 45 ms and $\Delta = 30$ ms.

<u>Histology</u>

935 936

938

939

953

954 955

972

973

974

After MRI, samples underwent standard histological procedures (i.e., dehydration, paraffine 940 embedding) within the same histology cassette in which they were imaged. We then cut two 941 4 µm-thick histological sections at known radiographic position (one per MRI slice) with a 942 microtome, and stained them with HE. We performed cuts following the same direction of 943 the virtual cuts performed by MRI slicing. We placed stained material on standard 944 microscopy slides, and acquired digital images with a Hamamatsu C9600-12 slide scanner 945 at a pixel resolution of 0.227 μ m (40× magnification). An experienced pathologist (S.S.) 946 inspected the images and assessed them qualitatively. We processed digital histological 947 images with the automatic cell detection tool of QuPath (32), obtaining per-cell 948 characteristic area A and diameter $l = \sqrt{\frac{4}{\pi}}A$. Afterwards, we split histological images into 949 386 μ m × 386 μ m patches, matching the in-plane MRI resolution, and computed 950 characteristic volume-weighted cell size νCS_{histo} and intra-cellular area fraction F_{histo} 951 patch-by-patch, similarly to (42). vCS_{histo}, defined as 952

 $vCS_{histo} = \left(\frac{< l^7 >}{< l^3 >}\right)^{\frac{1}{4}}, (11)$

is a better counterpart of dMRI cell size metrics than the arithmetic mean cell size 956 $aCS_{histo} = < l > (7, 42)$, since the dMRI signal is intrinsically volume-weighted (i.e., larger 957 cells contribute more to the signal than smaller cells). Conversely, F_{histo} is the fraction of 958 patch area occupied by the intra-cellular space, and is therefore the counterpart of quantity 959 F_{MRI} in Eq. 9. We accounted for biases coming from: i) estimating the size of 3D objects 960 from 2D views (bias 1), ii) tissue shrinkage (bias 2), by rescaling vCS_{histo} and CD_{histo}. The 961 final estimate of vCS_{histo} was 1.4616 times larger than the value obtained from direct image 962 processing $(1.148 \times 1.2732 = 1.4616)$, where 1.2732 was derived from the theory of spherical 963 caps and accounts for bias 1, while 1.148 accounts for bias 2, and corresponds to a plausible 964 shrinkage of 12.9% following dehydration, clearing and paraffin embedding (57)). The final 965 estimate of CD_{histo} was instead 1.318 times smaller than the value derived from direct 966 image processing, since 1 mm² of shrunk tissue corresponds to 1.148×1.148 mm² = 1.318967 mm² of unprocessed tissue for a shrinkage factor of 12.9% (57). Lastly, we co-registered 968 the L_{histo} and F_{histo} maps to their corresponding MRI slice, using a warping transformation 969 estimated via symmetric diffeomorphic registration of the specimen manual outlines (42) in 970 971 DiPy (67).

Clinical data

Cohort description

We obtained data from patients suffering from advanced solid tumours, recruited for an 975 ongoing imaging study approved by the Vall d'Hebron University Hospital Ethics 976 committee (PR(AG)29/2020). Patients, potentially eligible for a phase I immunotherapy 977 trial at VHIO (Barcelona, Spain), provided informed written consent to participate in the 978 979 imaging study. We included data from 33 patients with liver malignancies (mean/std of age: 62.91/12.34 year; 16 male, 17 female), of which 3 suffered from primary HCC, while 30 980 981 had liver metastases from different primary cancers (10 colon, 8 melanoma, 3 rectal, 2 ovarian, 2 gastric, 2 breast, 1 renal, 1 endometrial, 1 ureteral). We scanned 11 patients on a 982

1.5T Siemens Avanto system, while 22 on a 3T GE SIGNA Pioneer system. We obtained 983 984 baseline dMRI scans (i.e., acquired immediately before starting immunotherapy), and digitised HE-stained biopsies from one of the imaged liver tumours. In this study, we used 985 biopsies from 18 patients (6 scanned at 1.5T, 12 at 3T), which we collected after baseline 986 dMRI. 30 out of 33 patients effectively entered the immunotherapy trial after screening. For 987 this subset of 30 patients, we obtained clinical outcome information in the form of standard 988 PFS. The PFS represents the temporal lag between therapy starting date and progression or 989 990 death (whichever occurs first), with progression determined via RECIST (13) on standardof-care CT imaging, or in case of established clinical worsening. 991

<u>MRI</u>

992

993

994 We imaged patients at the level of the abdomen on two MRI machines. We scanned 11 patients on a 1.5T Siemens Avanto scanner using the vendor 18-channel body coil for 995 detection. The protocol included an anatomical, T2-weighted RARE fast spin echo scan, 996 with salient parameters: resolution: $1.4 \times 1.4 \times 5 \text{ mm}^3$; 32 slices; TR = 4500 ms; TE = 82 997 ms; echo train length: 29; NEX = 8; GRAPPA = 2. It also included a fat-suppressed DW 998 TRSE (Fig. S17B) EPI scan (total scan time: 16 minutes). It featured: resolution: 1.9×1.9 999 \times 6 mm³; 32 slices; TR = 7900 ms; bandwidth 1430 Hz/pixel; averaging of 3 orthogonal 1000 diffusion directions \times 2 signal averages (effective NEX = 6); GRAPPA factor of 2; 6/8 1001 partial Fourier imaging. The dMRI protocol consisted of $b = \{0, 50, 100, 400, 900, 1200,$ 1002 1600} s/mm² images, each acquired for $TE = \{93, 105, 120\}$ ms, for a total of 21 images. 1003 The phase encoding direction was anterior-posterior, and one additional image (b = 0 s/mm²; 1004 TE = 93 ms) was acquired with reversed phase encoding polarity. The gradient timings (Fig. 1005 S17B) were: $\delta_1 = 8.9$ ms, $\delta_2 = 17.6$ ms, $\delta_3 = 20.4$ ms, $\delta_4 = 6.0$ ms, $\Delta_{1,2} = 17.4$ ms and $\Delta_{1,4} =$ 1006 63.9 ms when TE = 93 ms; δ_1 = 13.2 ms, δ_2 = 19.3 ms, δ_3 = 24.8 ms, δ_4 = 7.7 ms, $\Delta_{1,2}$ = 21.7 1007 ms and $\Delta_{1,4} = 74.2$ ms when TE = 105 ms; $\delta_1 = 18.9$ ms, $\delta_2 = 21.0$ ms, $\delta_3 = 30.5$ ms, $\delta_4 =$ 1008 9.5 ms, $\Delta_{1,2} = 27.5$ ms and $\Delta_{1,4} = 87.5$ ms when TE = 120 ms. The b-value as a function of 1009 the gradient timings, the gradient strength G and the proton gyromagnetic ration γ can be 1010 expressed as 1011

$$b = \gamma^2 G^2 \left(\delta_1^2 (\Delta_{1,2} - \delta_1) + \frac{2}{3} (\delta_1 + \delta_2)^3 + (\delta_1 + \delta_2 - \delta_3)^2 (\Delta_{1,4} - \Delta_{1,2} - \delta_2 - \delta_3) \right).$$
(12)

Moreover, we scanned 22 patients on a 3T GE SIGNA Pioneer scanner, using the vendor 1016 48-channel torso coil for signal reception, with 32 channels enabled for detection. The 1017 protocol included an anatomical, respiratory-gated T2-weighted RARE fast spin echo scan, 1018 with salient parameters: resolution: $1.4 \times 1.4 \times 6 \text{ mm}^3$; 32 slices; TR = 4615 ms; TE = 52.86 1019 ms; echo train length: 16. It also included a respiratory-gated, fat-suppressed PGSE (Fig. 1020 S10A) EPI scan (total scan time: 16 minutes). It featured: resolution: $2.4 \times 2.4 \times 6 \text{ mm}^3$; 32 1021 slices; TR = 6000 ms; bandwidth 1953 Hz/pixel; averaging of 3 orthogonal diffusion 1022 directions \times 2 signal averages (effective NEX = 6); ASSET factor of 2. The dMRI protocol 1023 consisted of $b = \{0, 50, 100, 400, 900, 1200, 1500\}$ s/mm² images, each acquired for TE = 1024 {75, 90, 105} ms, for a total of 21 images. The gradient timings (Fig. S17A) were: gradient 1025 duration δ of $\delta = \{0.0, 3.9, 5.2, 9.2, 15.0, 18.2, 21.0\}$ ms for the b-values acquired at TE = 1026 75 ms, and $\delta = \{0.0, 3.9, 5.2, 9.2, 13.0, 15.8, 18.5\}$ ms for those acquired at both TE = 90 1027 ms and 105 ms; gradient separation Δ of $\Delta = \{0.0, 27.8, 29.0, 33.0, 28.7, 31.8, 34.7\}$ ms for 1028 the b-values acquired at TE = 75 ms and $\Delta = \{0.0, 27.8, 29.0, 33.0, 37.0, 39.6, 42.3\}$ ms for 1029 those acquired at both TE = 90 ms and TE = 105 ms. 1030

dMRI post-processing consisted of slice-wise Python MP-PCA denoising (kernel size: $5 \times$ 1032 1033 5) (65); Gibbs unringing (66) based on MRTrix3; motion correction via affine coregistration (68); EPI distortion correction based on FSL (69) (on the 1.5T data only). An 1034 experienced radiologists (R.P.L.) segmented tumours on the T2-w anatomical scan, 1035 enabling per-patient tumour volume calculation. Afterwards, we warped the tumour mask 1036 to dMRI space using a non-linear transformation estimated with ANTs (70). Then, we fitted 1037 the 5 dMRI models object of this article on a voxel-by-voxel basis, fixing again f_V and $T2_T$ 1038 to previously computed values (64) (fitting bounds: [0; 1] for f_V ; [20; 140] ms for $T2_T$). 1039 Fitting bounds for tissue parameters were: [0; 1] for f_I ; [0.8; 3.0] μ m² ms⁻¹ for $D_{0,I}$; [8; 40] 1040 μ m for the vCS parameter L; [0.8; 3.0] μ m² ms⁻¹ for $D_{E,\infty}$ in models Diff-in-ex and Diff-in-1041 exTD, and [1.75; 3.0] µm² ms⁻¹ in models Diff-in-exFast and Diff-in-exTDFast; [0; 10] µm² 1042 for β in models *Diff-in-ex-TD* and *Diff-in-exTDFast*. 1043

We fitted the 5 dMRI models twice: once, on images acquired at a b-value $b > 100 \text{ s/mm}^2$, 1045 to suppress vascular signals (fitting to the whole image set); afterwards, to b > 900 s/mm² 1046 images, to also minimise extra-cellular signal contributions (high b-value fitting). For scans 1047 performed on the 1.5T Siemens system, based on a DW TRSE sequence (Fig. S10B), we 1048 used $\Delta_{1,2} + \delta_2$ in place of Δ in Eq. 6 for the extra-cellular ADC. Moreover, we replaced Eq. 1049 4 with a numerical implementation of the intra-cellular model of restricted diffusion within 1050 spheres. This implementation was based on a Radial Basis Function regressor trained on 1051 synthetic signals generated with Monte Carlo random walks within meshed spheres. We 1052 performed the simulations with the freely available MCDC simulator (71), varying the intra-1053 cellular diffusivity $D_{0,I}$ in [0.8; 3.0] μ m² ms⁻¹ and the cell diameter L in [8; 40] μ m. We 1054 used 12 linearly spaced values for each of $D_{0,I}$ and L, for a total of $12 \times 12 = 144$ simulations. 1055 Finally, we computed routine ADC and diffusion excess kurtosis K by fitting Eq. 10 on b >1056 100 s/mm² images acquired at the shortest TE with in-house Python code. 1057

<u>Histology</u>

1044

1058

1059

1078

In patients, we performed ultrasound-guided biopsies of one liver tumour at the Vall 1060 d'Hebron University Hospital of Barcelona (Spain). The biological material underwent 1061 standard histological processing and staining with HE. We acquired digital images of the 1062 stained biopsies using a Hamamatsu C9600-12 slide scanner (resolution: 0.454 µm; 20× 1063 magnification). An experienced pathologist (S.S.) assessed the images and drew manually 1064 a region-of-interest (ROI) outlining the tumour tissue in each HE image. In parallel, an 1065 experienced radiologist (R.P.L.) inspected the ultrasound scan jointly with MR images, and 1066 outlined on MRI the tumour from which the biopsy was taken. We processed HE images 1067 with QuPath and computed per-biopsy volume-weighted cell size vCS_{histo} , intra-cellular 1068 area fraction F_{histo} and cell density per unit area CD_{histo} , as previously described for the 1069 mouse data. Again, we corrected vCS_{histo} and CD_{histo} for biases. The final estimate of 1070 vCS_{histo} was 1.503 times larger than the value obtained from direct image processing 1071 $(1.1806 \times 1.2732 = 1.503)$, where 1.2732 accounts again for biases from 2D sectioning, while 1072 1.1806 accounts for a plausible tissue shrinkage of 15.3% following fixation, dehydration, 1073 clearing and paraffin embedding (57)). The final estimate of CD_{histo} was instead 1.3938 1074 times smaller than the value derived from direct image processing, since 1 mm² of shrunk 1075 tissue corresponds to $1.1806 \times 1.1806 \text{ mm}^2 = 1.3938 \text{ mm}^2$ of unprocessed tissue for a 1076 shrinkage factor of 15.3% (57). 1077

1079Statistical analyses

1080We performed three analyses to i) select the dMRI model providing metrics with the highest1081fidelity to histology; ii) assess the correlation between MRI and histology metrics; iii)

demonstrate the potential of the new dMRI model in the context of cancer immunotherapy. For the analyses listed above, we computed mean and standard deviation of all MRI and histology metrics within the mouse liver samples. Moreover, we computed the mean and standard deviation of all MRI metrics within a mask containing all liver tumours, as well as on the tumour from which the biopsy was taken.

1089 <u>dMRI model selection</u>

1082

1083

1084

1085

1086 1087 1088

1090

1091

1092

1093 1094

1103 1104 1105

1111

1112

1113

1114

1115

1116

1117

1118111911201121

1126

We performed histology-informed model selection using the *MRI-histology Total Correlation Score* (TCS). We carried out the selection independently on dMRI metrics obtained i) fitting the signal models to the whole image set, or ii) fitting the signal models only to high b-value images.

TCS selects the model providing the highest Pearson's correlation coefficients between 1095 νCS_{MRI} and νCS_{histo} , and between F_{MRI} and F_{histo} . TCS focusses on the overall sensitivity 1096 of a dMRI model towards the underlying histology (i.e., correlation), rather than on the 1097 accuracy of the numerical estimation of the histological properties themselves. This is 1098 justified by noting that in certain applications it may be relevant to detect, for example, 1099 changes in MRI apparent cell size from normative reference values, even if the numerical 1100 value of such an apparent cell size contains systematic biases with respect to the true 1101 histological cell size. Practically, TCS selects the model that maximises 1102

$$TCS = r(vCS_{MRI}, vCS_{histo}) + r(F_{MRI}, F_{histo}), (13)$$

1106 where $r(vCS_{MRI}, vCS_{histo})$ and $r(F_{MRI}, F_{histo})$ are the Pearson's correlation coefficients of 1107 vCS_{MRI} and F_{MRI} with their histological counterparts vCS_{histo} and F_{histo} . The correlation 1108 between CD_{MRI} and CD_{histo} was not included in Eq. 13 since CD_{MRI} is fully determined 1109 analytically from vCS_{MRI} and F_{MRI} . For the computation of the TCS index, we pooled 1100 together mouse and human data (N = 25).

For reference, we also performed model selection using a *Histology Fidelity Criterion* (HFC) and the well-known *Bayesian Information Criterion* (BIC) (33), a common model selection technique in dMRI model development (34). HFC rewards the models providing the best accuracy in the numerical estimation of histological cell size and intra-cellular fraction estimation, i.e., the model providing vCS_{MRI} as close as possible to vCS_{histo} , and F_{MRI} as close as possible to F_{histo} . Practically, HFC selects the candidate model that minimises

$$HFC = \frac{|vCS_{MRI} - vCS_{histo}|}{vCS_{histo}} + \frac{|F_{MRI} - F_{histo}|}{F_{histo}}.$$
 (14)

1122Information on CD_{MRI} and CD_{histo} was not included in Eq. 14 since CD_{MRI} is not a degree1123of freedom of the dMRI models (it is fully determined analytically once vCS_{MRI} and F_{MRI} 1124are fitted), and also because CD_{MRI} and CD_{histo} have different units, so they are not directly1125comparable.

BIC selects the model providing the best goodness of fit, penalising complexity. BIC can be computed from the value of the minimised fitting objective function $f_{obj} = -ln(\lambda)$, where λ is maximum likelihood, as

1133

1134

1135

1136 1137

1144

1157

1166

$$BIC = Pln(N) - ln(\lambda), (15)$$

where P is the number of estimated model parameters, and N the number of dMRI measurements used for the fitting. We performed model selection based on BIC on a voxelby-voxel basis, and selected a winning model for each mouse liver and patient by majority voting across voxels.

1138 Simulated dMRI model selection

We corroborated results from *ex vivo* and *in vivo* dMRI with computer simulations, in which dMRI model selection was performed on synthetic dMRI signals. We synthesised signals via Monte Carlo diffusion random walks for each of the three protocols considered in this study, i.e., for the PGSE protocols used in the 9.4T scanner *ex vivo* and in the 3T *in vivo*, and for the TRSE protocol used in the 1.5T scanner *in vivo*.

We performed Monte Carlo simulations with the freely available, open-source MCDC 1145 simulator (71), seeding random walkers in a substrate made of packed spherical cells of 1146 identical diameter (Fig. S5), a common geometric model in body dMRI (6, 19, 22, 23). We 1147 controlled the intra-sphere fraction F by adding gaps of increasing size in-between abutting 1148 spheres, which we packed in an ideal cubic lattice. We probed 4 different values of F1149 (approximately equal to 0.197, 0.323, 0.406, 0.523; notice that the maximum theoretical 1150 value of F for cubic lattice packing is equal to 0.5236). For each value of F, we varied the 1151 cell diameter (8, 16, 22 and 30 um), intra-sphere diffusivity (10 linearly-spaced values in 1152 1153 respectively) and extra-sphere intrinsic diffusivity (again, 10 linearly-spaced values in the 1154 ranges [0.8; 2.6] μ m² ms⁻¹ and [0.8; 3.0] μ m² ms⁻¹ for the *ex vivo* and *in vivo* protocols 1155 respectively), generating a total of 1600 synthetic voxels. 1156

We corrupted synthetic signals with Rician noise (signal-to-noise ratio at b = 0 of 30), and 1158 then processed them in the same way as done for actual MRI measurements, Briefly, we 1159 first fitted the five candidate models for both fitting strategy (whole image set; high b-value 1160 image subset), and then performed dMRI model selection according to the TCS, HFC and 1161 BIC criteria. For TCS ranking, we calculated correlation coefficients between reference and 1162 estimated vCS and F pooling results from all 1600 synthetic voxels. Conversely, for HFC 1163 and BIC ranking, we selected in each synthetic voxel the model minimising each of HFC 1164 and BIC, and then counted the proportion of voxels in which each model was selected. 1165

1167 <u>dMRI-histology correlation analysis</u>

We computed mean and standard deviation of all MRI and histology metrics within the 1168 mouse liver samples. Moreover, we computed the mean and standard deviation of all MRI 1169 metrics within a mask containing all liver tumours, as well as on the tumour from which the 1170 biopsy was taken. We pooled together MRI and histology metrics from mice and patients 1171 to calculate the Pearson's linear correlation coefficient r among each possible pair of 1172 metrics, visualising these are correlation matrices. ADC was normalised to the ADC of the 1173 PBS solutions (mouse livers) and to the free water diffusivity at 37 °C (3.0 μ m² ms⁻¹), to 1174 account for differences in temperature between the preclinical and clinical data set. The 1175 sample size was N = 25 (N = 7 data points from mice plus N = 18 from patients). We 1176 consider correlations to be weak, moderate, and strong when |r| < 0.4, $|r| \ge 0.4$ but |r| < 0.41177 0.6, and $|r| \ge 0.6$ respectively. 1178

1181 <u>Response assessment in immunotherapy</u>

We studied mean values of *in vivo* dMRI metrics within liver tumours at baseline to assess 1182 whether these could stratify the probability of progression under immunotherapy, as 1183 measured by our clinical outcome PFS (measured in days). The sample size was N = 30. 1184 Firstly, we performed the stratification after binarising all MRI metrics as lower/higher than 1185 the median of the cohort. This allowed us to obtain two groups of patients, i.e., patients 1186 whose dMRI metric at baseline was either low or high. We evaluated group-wise survival 1187 curves with the Kaplan-Meier estimator, and compared the two curves with a log-rank test. 1188 We confirmed results from such a statistical model with a proportional hazard Cox 1189 regression, where the binarised MRI metric was the only regressor. Afterwards, we 1190 performed a second patient stratification, but without binarising MRI metrics, i.e., using 1191 them as continuous regressors. We fitted a proportional hazard Cox model using each dMRI 1192 metric in turn as the only regressor (in the form of a z-score), and then fitted the statistical 1193 model again but including including age, sex and total baseline tumour volume as 1194 confounding factors. We considered p-values of 0.05 or lower as significant. We performed 1195 all survival analyses in Python, using the freely available *lifelines* library. 1196

1199 Acknowledgments

1197 1198

We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d'Hebron University Hospital and at the Vall d'Hebron Institute of Oncology in Barcelona (Spain), without whom this study would not have been possible. We are also thankful to the Vall d'Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance, and to past and present members of the Radiomics group for useful discussion and advice. Finally, we would like to express our sincere gratitude to all patients and their families for dedicating their time to research.

1207 Funding: VHIO would like to acknowledge: the State Agency for Research (Agencia 1208 Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa 1209 (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing 1210 research facilities and equipment and the CERCA Programme from the Generalitat de 1211 Catalunya for their support on this research. This research has been supported by PREdICT, 1212 sponsored by AstraZeneca. This study has been co-funded by the European Regional 1213 Development Fund/European Social Fund 'A way to make Europe' (to R.P.L.). R.P.L is 1214 supported by the "la Caixa" Foundation CaixaResearch Advanced Oncology Research 1215 Program, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award 1216 (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for 1217 Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 1218 and PI21/01019), the Asociación Española Contra 1219 el Cancer (AECC) (PRYCO211023SERR) and the Generitat de Catalunya Agency for Management of 1220 University and Research Grants of Catalonia (AGAUR) (2023PROD00178). This research 1221 has been funded by the CaixaResearch Advanced Oncology Research Program supported 1222 1223 by "La Caixa" Foundation (to R.P.L.). The project that gave rise to these results received the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship 1224 "LCF/BQ/PR22/11920010" (funding F.G, A.V., 1225 code is and A.G) and "LCF/BQ/PI20/11760033" (funding I.C.S). I.C.S. also receives the support of the European 1226 Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-1227 Curie grant agreement No 847648. This research has received support from the Beatriu de 1228 1229 Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support 1230

1271 1272 1273	
	-
	current form for publication.
1269 1270	AstraZeneca. AstraZeneca, Siemens and GE did not influence the acquisition and analysis of the data, the interpretation of the results, or the decision to submit the manuscript in its
1268	the Vall d'Hebron Institute of Oncology (Barcelona), and is now an employee of
1267	Siemens Healthineers. P.G.P.G works for GE HealthCare. K.B. worked as a researcher at the Vall d'Hebrer Institute of Oncelegy (Paraelene) and is now an employee of
1266	Competing interests: This study received funding from AstraZeneca. M.Vid. works for Sigmong Healthingers, B.C.B.C. works for CE HealthCare, K.B. worked as a researcher at
1265	Compating interestor This study received funding from Astro Zanges MULL modes for
1264	Writing—review & editing: all authors
1263	Writing—original draft: F.G., R.P.L., K.B., M.P.
1262	Supervision: F.G., R.P.L., E.G., R.T., P.N., J.M.
1261	Funding acquisition: R.P.L., E.G., R.T., P.N., J.M., F.G., K.B., I.C.S.
1260	Project administration: F.G., R.P.L., K.B., E.G., P.N., R.T., J.M., I.C.S.
1259	Data curation: F.G., R.P.L., K.B., A.V., G.S., I.C.S., A.G.
1258	Software: F.G., K.B., A.G.
1257	Visualization: F.G.
1256	Formal analysis: F.G.
1255	Resources: R.P.L., F.G., P.N., J.M., E.G., N.R., M.E., V.G., M.Vid., P.G.PG, I.B.
1254	N.R., M.E., M.Vie., R.T., P.N., J.M., E.G.
1253	Investigation: F.G., R.P.L., K.B., I.C.S., I.B., S.S., G.S., A.G., V.G., J.F.C., X.M., R.M.,
1252	Methodology: F.G., R.P.L., K.B., M.P., A.G.
1251	Conceptualization: F.G., R.P.L., K.B., M.P., E.G., R.T., P.N., J.M.
1250	Author contributions:
1249	
1248	UK Research and Innovation: MR/T020296/2 (M.P.)
1247	PRE2022-102586 (A.G.)
1246	Agencia Estatal de Investigación: CEX2020-001024-S/AEI/10.13039/501100011033,
1245	Generalitat de Catalunya: BP3 801370, 2019 BP 00182 (K.B.), 2023PROD00178 (R.P.L.)
1244	European Union's Horizon 2020 Marie Sklodowska-Curie: 847648 (I.C.S.)
1243	"la Caixa" Foundation: LCF/BQ/PI20/11760033 (I.C.S.)
1242	"la Caixa" Foundation: LCF/BQ/PR22/11920010 (F.G., A.V., A.G.)
1241	"la Caixa" Foundation: CaixaResearch Advanced Oncology Research Program (R.P.L.)
1240	Fero Foundation (R.P.L.)
1239	Prostate Cancer Foundation: 18YOUN19 (R.P.L.)
1238	Instituto de Salud Carlos III: PI18/01395 and PI21/01019 (R.P.L.)
1237	CRIS Foundation: TALENT19-05 (R.P.L.)
1236	AstraZeneca: PREdICT (R.P.L, E.G., P.N., R.T.)
1235	
1234	fellowship (PRE2022-102586).
1233	Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD
1232	reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI
1231	from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370;

- N. Weiskopf, L. J. Edwards, G. Helms, S. Mohammadi, E. Kirilina, Quantitative magnetic resonance imaging of brain anatomy and in vivo histology. *Nature Reviews Physics*. 3, 570– 588 (2021).
- A. M. Jarrett, A. S. Kazerouni, C. Wu, J. Virostko, A. G. Sorace, J. C. DiCarlo, D. A.
 Hormuth 2nd, D. A. Ekrut, D. Patt, B. Goodgame, S. Avery, T. E. Yankeelov, Quantitative

1281 1282		magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting. <i>Nat. Protoc.</i> 16 , 5309–5338 (2021).
1283 1284	3.	V. G. Kiselev, Fundamentals of diffusion MRI physics. <i>NMR Biomed.</i> 30 (2017), doi:10.1002/nbm.3602.
1285 1286 1287	4.	D. S. Novikov, E. Fieremans, S. N. Jespersen, V. G. Kiselev, Quantifying brain microstructure with diffusion MRI: Theory and parameter estimation. <i>NMR Biomed.</i> 32 , e3998 (2019).
1288 1289	5.	D. Le Bihan, Looking into the functional architecture of the brain with diffusion MRI. <i>Nat. Rev. Neurosci.</i> 4 , 469–480 (2003).
1290 1291 1292	6.	E. Panagiotaki, S. Walker-Samuel, B. Siow, S. P. Johnson, V. Rajkumar, R. B. Pedley, M. F. Lythgoe, D. C. Alexander, Noninvasive quantification of solid tumor microstructure using VERDICT MRI. <i>Cancer Res.</i> 74 , 1902–1912 (2014).
1293 1294	7.	J. Veraart, D. Nunes, U. Rudrapatna, E. Fieremans, D. K. Jones, D. S. Novikov, N. Shemesh, Noninvasive quantification of axon radii using diffusion MRI. <i>Elife</i> . 9 , e49855 (2020).
1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309	8.	J. Cohen-Adad, E. Alonso-Ortiz, M. Abramovic, C. Arneitz, N. Atcheson, L. Barlow, R. L. Barry, M. Barth, M. Battiston, C. Büchel, M. Budde, V. Callot, A. J. E. Combes, B. De Leener, M. Descoteaux, P. L. de Sousa, M. Dostál, J. Doyon, A. Dvorak, F. Eippert, K. R. Epperson, K. S. Epperson, P. Freund, J. Finsterbusch, A. Foias, M. Fratini, I. Fukunaga, C. A. M. G. Wheeler-Kingshott, G. Germani, G. Gilbert, F. Giove, C. Gros, F. Grussu, A. Hagiwara, PG. Henry, T. Horák, M. Hori, J. Joers, K. Kamiya, H. Karbasforoushan, M. Keřkovský, A. Khatibi, JW. Kim, N. Kinany, H. Kitzler, S. Kolind, Y. Kong, P. Kudlička, P. Kuntke, N. D. Kurniawan, S. Kusmia, R. Labounek, M. M. Laganà, C. Laule, C. S. Law, C. Lenglet, T. Leutritz, Y. Liu, S. Llufriu, S. Mackey, E. Martinez-Heras, L. Mattera, I. Nestrasil, K. P. O'Grady, N. Papinutto, D. Papp, D. Pareto, T. B. Parrish, A. Pichiecchio, F. Prados, À. Rovira, M. J. Ruitenberg, R. S. Samson, G. Savini, M. Seif, A. C. Seifert, A. K. Smith, S. A. Smith, Z. A. Smith, E. Solana, Y. Suzuki, G. Tackley, A. Tinnermann, J. Valošek, D. Van De Ville, M. C. Yiannakas, K. A. Weber 2nd, N. Weiskopf, R. G. Wise, P. O. Wyss, J. Xu, Generic acquisition protocol for quantitative MRI of the spinal cord. <i>Nat. Protoc.</i> 16 , 4611–4632 (2021).
1310 1311 1312	9.	G. C. Baxter, M. J. Graves, F. J. Gilbert, A. J. Patterson, A Meta-analysis of the Diagnostic Performance of Diffusion MRI for Breast Lesion Characterization. <i>Radiology</i> . 291 , 632–641 (2019).
1313 1314	10.	H. Donato, M. França, I. Candelária, F. Caseiro-Alves, Liver MRI: From basic protocol to advanced techniques. <i>Eur. J. Radiol.</i> 93 , 30–39 (2017).
1315 1316	11.	E. B. Tapper, A. SF. Lok, Use of Liver Imaging and Biopsy in Clinical Practice. <i>N. Engl. J. Med.</i> 377 , 756–768 (2017).
1317 1318 1319	12.	D. I. Tsilimigras, P. Brodt, PA. Clavien, R. J. Muschel, M. I. D'Angelica, I. Endo, R. W. Parks, M. Doyle, E. de Santibañes, T. M. Pawlik, Liver metastases. <i>Nat Rev Dis Primers</i> . 7 , 27 (2021).
1320 1321	13.	E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D.

- Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST 1322 guideline (version 1.1). Eur. J. Cancer. 45, 228-247 (2009). 1323 14. J. Y. Buikhuisen, A. Torang, J. P. Medema, Exploring and modelling colon cancer inter-1324 tumour heterogeneity: opportunities and challenges. Oncogenesis. 9, 66 (2020). 1325 15. I. Vitale, E. Shema, S. Loi, L. Galluzzi, Intratumoral heterogeneity in cancer progression and 1326 response to immunotherapy. Nat. Med. 27, 212-224 (2021). 1327 16. A. D. Waldman, J. M. Fritz, M. J. Lenardo, A guide to cancer immunotherapy: from T cell 1328 basic science to clinical practice. Nat. Rev. Immunol. 20, 651-668 (2020). 1329 17. C. Pilard, M. Ancion, P. Delvenne, G. Jerusalem, P. Hubert, M. Herfs, Cancer 1330 immunotherapy: it's time to better predict patients' response. Br. J. Cancer. 125, 927–938 1331 (2021). 1332 18. J. P. B. O'Connor, E. O. Aboagye, J. E. Adams, H. J. W. L. Aerts, S. F. Barrington, A. J. 1333 Beer, R. Boellaard, S. E. Bohndiek, M. Brady, G. Brown, D. L. Buckley, T. L. Chenevert, L. 1334 P. Clarke, S. Collette, G. J. Cook, N. M. deSouza, J. C. Dickson, C. Dive, J. L. Evelhoch, C. 1335 Faivre-Finn, F. A. Gallagher, F. J. Gilbert, R. J. Gillies, V. Goh, J. R. Griffiths, A. M. 1336 Groves, S. Halligan, A. L. Harris, D. J. Hawkes, O. S. Hoekstra, E. P. Huang, B. F. Hutton, 1337 E. F. Jackson, G. C. Jayson, A. Jones, D.-M. Koh, D. Lacombe, P. Lambin, N. Lassau, M. O. 1338 Leach, T.-Y. Lee, E. L. Leen, J. S. Lewis, Y. Liu, M. F. Lythgoe, P. Manoharan, R. J. 1339 Maxwell, K. A. Miles, B. Morgan, S. Morris, T. Ng, A. R. Padhani, G. J. M. Parker, M. 1340 Partridge, A. P. Pathak, A. C. Peet, S. Punwani, A. R. Reynolds, S. P. Robinson, L. K. 1341 Shankar, R. A. Sharma, D. Soloviev, S. Stroobants, D. C. Sullivan, S. A. Taylor, P. S. Tofts, 1342 G. M. Tozer, M. van Herk, S. Walker-Samuel, J. Wason, K. J. Williams, P. Workman, T. E. 1343 Yankeelov, K. M. Brindle, L. M. McShane, A. Jackson, J. C. Waterton, Imaging biomarker 1344 roadmap for cancer studies. Nat. Rev. Clin. Oncol. 14, 169-186 (2017). 1345 19. X. Jiang, J. Xu, J. C. Gore, Mapping hepatocyte size in vivo using temporal diffusion 1346 spectroscopy MRI. Magn. Reson. Med. 84, 2671-2683 (2020). 1347 20. E. Panagiotaki, R. W. Chan, N. Dikaios, H. U. Ahmed, J. O'Callaghan, A. Freeman, D. 1348 Atkinson, S. Punwani, D. J. Hawkes, D. C. Alexander, Microstructural Characterization of 1349 Normal and Malignant Human Prostate Tissue With Vascular, Extracellular, and Restricted 1350 Diffusion for Cytometry in Tumours Magnetic Resonance Imaging. Invest. Radiol. 50, 218 1351 1352 (2015). 21. R. Gardier, J. L. Villarreal Haro, E. J. Canales-Rodríguez, I. O. Jelescu, G. Girard, J. Rafael-1353 Patiño, J.-P. Thiran, Cellular Exchange Imaging (CEXI): Evaluation of a diffusion model 1354 including water exchange in cells using numerical phantoms of permeable spheres. Magn. 1355 Reson. Med. (2023), doi:10.1002/mrm.29720. 1356 22. E. Hoffmann, M. Gerwing, S. Niland, R. Niehoff, M. Masthoff, C. Geyer, L. Wachsmuth, E. 1357 Wilken, C. Höltke, W. L. Heindel, V. Hoerr, R. Schinner, P. Berger, T. Vogl, J. A. Eble, B. 1358 Maus, A. Helfen, M. Wildgruber, C. Faber, Profiling specific cell populations within the 1359 inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI. J 1360
- 1361 *Immunother Cancer.* **11**, e006092 (2023).

1362 1363 1364	23.	X. Jiang, S. Dudzinski, K. E. Beckermann, K. Young, E. McKinley, O. J McIntyre, J. C. Rathmell, J. Xu, J. C. Gore, MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. <i>J Immunother Cancer</i> . 8 (2020), doi:10.1136/jitc-2019-000328.
1365 1366 1367 1368 1369	24.	Z. Ye, R. L. Price, X. Liu, J. Lin, Q. Yang, P. Sun, A. T. Wu, L. Wang, R. H. Han, C. Song, R. Yang, S. E. Gary, D. D. Mao, M. Wallendorf, J. L. Campian, JS. Li, S. Dahiya, A. H. Kim, SK. Song, Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology. <i>Clin. Cancer Res.</i> 26 , 5388–5399 (2020).
1370 1371 1372	25.	A. F. Howard, J. Mollink, M. Kleinnijenhuis, M. Pallebage-Gamarallage, M. Bastiani, M. Cottaar, K. L. Miller, S. Jbabdi, Joint modelling of diffusion MRI and microscopy. <i>Neuroimage</i> . 201 , 116014 (2019).
1373 1374	26.	D. S. Novikov, V. G. Kiselev, S. N. Jespersen, On modeling. <i>Magn. Reson. Med.</i> 79 , 3172–3193 (2018).
1375 1376	27.	J. Xu, J. Xie, N. B. Semmineh, S. P. Devan, X. Jiang, J. C. Gore, Diffusion time dependency of extracellular diffusion. <i>Magn. Reson. Med.</i> 89 , 2432–2440 (2023).
1377 1378	28.	C. H. Neuman, Spin echo of spins diffusing in a bounded medium. J. Chem. Phys. 60, 4508–4511 (1974).
1379 1380 1381 1382 1383	29.	C. C. Conlin, C. H. Feng, A. E. Rodriguez-Soto, R. A. Karunamuni, J. M. Kuperman, D. Holland, R. Rakow-Penner, M. E. Hahn, T. M. Seibert, A. M. Dale, Improved Characterization of Diffusion in Normal and Cancerous Prostate Tissue Through Optimization of Multicompartmental Signal Models. <i>J. Magn. Reson. Imaging.</i> 53 , 628–639 (2021).
1384 1385 1386 1387	30.	J. H. Jensen, J. A. Helpern, A. Ramani, H. Lu, Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. <i>in Medicine: An</i> (2005) (available at https://onlinelibrary.wiley.com/doi/abs/10.1002/mrm.20508).
1388 1389 1390 1391	31.	S. J. Hectors, S. Semaan, C. Song, S. Lewis, G. K. Haines, A. Tewari, A. R. Rastinehad, B. Taouli, Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Composition-A Hypothesis-generating Study. <i>Radiology</i> . 286 , 918–928 (2018).
1392 1393 1394 1395	32.	P. Bankhead, M. B. Loughrey, J. A. Fernández, Y. Dombrowski, D. G. McArt, P. D. Dunne, S. McQuaid, R. T. Gray, L. J. Murray, H. G. Coleman, J. A. James, M. Salto-Tellez, P. W. Hamilton, QuPath: Open source software for digital pathology image analysis. <i>Sci. Rep.</i> 7 , 16878 (2017).
1396	33.	G. Schwarz, Estimating the Dimension of a Model. <i>aos.</i> 6 , 461–464 (1978).
1397 1398 1399	34.	E. Panagiotaki, T. Schneider, B. Siow, M. G. Hall, M. F. Lythgoe, D. C. Alexander, Compartment models of the diffusion MR signal in brain white matter: a taxonomy and comparison. <i>Neuroimage</i> . 59 , 2241–2254 (2012).

- 1400 35. U. Ferizi, T. Schneider, E. Panagiotaki, G. Nedjati-Gilani, H. Zhang, C. A. M. Wheeler1401 Kingshott, D. C. Alexander, A ranking of diffusion MRI compartment models with in vivo
 1402 human brain data. *Magn. Reson. Med.* 72, 1785–1792 (2014).
- 36. M. Palombo, V. Valindria, S. Singh, E. Chiou, F. Giganti, H. Pye, H. C. Whitaker, D.
 Atkinson, S. Punwani, D. C. Alexander, E. Panagiotaki, Joint estimation of relaxation and
 diffusion tissue parameters for prostate cancer with relaxation-VERDICT MRI. *Sci. Rep.* 13,
 2999 (2023).
- X. Jiang, S. P. Devan, J. Xie, J. C. Gore, J. Xu, Improving MR cell size imaging by inclusion of transcytolemmal water exchange. *NMR Biomed.* 35, e4799 (2022).

38. A. B. Rosenkrantz, E. E. Sigmund, A. Winnick, B. E. Niver, B. Spieler, G. R. Morgan, C. H.
Hajdu, Assessment of hepatocellular carcinoma using apparent diffusion coefficient and
diffusion kurtosis indices: preliminary experience in fresh liver explants. *Magn. Reson. Imaging.* 30, 1534–1540 (2012).

- 39. W.-J. Tang, W. Yao, Z. Jin, Q.-C. Kong, W.-K. Hu, Y.-S. Liang, L.-X. Chen, S.-Y. Chen,
 Q.-Q. Zhang, X.-H. Wei, X.-D. Xu, Y. Guo, X.-Q. Jiang, Evaluation of the Effects of AntiPD-1 Therapy on Triple-Negative Breast Cancer in Mice by Diffusion Kurtosis Imaging and
 Dynamic Contrast-Enhanced Imaging. *J. Magn. Reson. Imaging.* 56, 1912–1923 (2022).
- 40. N. C. Martin, C. T. McCullough, P. G. Bush, L. Sharp, A. C. Hall, D. J. Harrison, Functional analysis of mouse hepatocytes differing in DNA content: volume, receptor expression, and effect of IFNgamma. *J. Cell. Physiol.* **191**, 138–144 (2002).
- 41. Z. Zhou, M.-J. Xu, B. Gao, Hepatocytes: a key cell type for innate immunity. *Cell. Mol. Immunol.* 13, 301–315 (2016).
- 42. F. Grussu, K. Bernatowicz, I. Casanova-Salas, N. Castro, P. Nuciforo, J. Mateo, I. Barba, R.
 Perez-Lopez, Diffusion MRI signal cumulants and hepatocyte microstructure at fixed
 diffusion time: Insights from simulations, 9.4T imaging, and histology. *Magn. Reson. Med.*(2022), doi:10.1002/mrm.29174.
- 43. M. Morawski, E. Kirilina, N. Scherf, C. Jäger, K. Reimann, R. Trampel, F. Gavriilidis, S.
 Geyer, B. Biedermann, T. Arendt, N. Weiskopf, Developing 3D microscopy with CLARITY
 on human brain tissue: Towards a tool for informing and validating MRI-based histology. *Neuroimage*. 182, 417–428 (2018).
- 44. I. O. Jelescu, J. Veraart, E. Fieremans, D. S. Novikov, Degeneracy in model parameter
 estimation for multi-compartmental diffusion in neuronal tissue. *NMR Biomed.* 29, 33–47
 (2016).
- 45. M. Nilsson, G. Eklund, F. Szczepankiewicz, M. Skorpil, K. Bryskhe, C.-F. Westin, C. Lindh,
 L. Blomqvist, F. Jäderling, Mapping prostatic microscopic anisotropy using linear and
 spherical b-tensor encoding: A preliminary study. *Magn. Reson. Med.* 86, 2025–2033 (2021).
- 46. E. Fokkinga, J. A. Hernandez-Tamames, A. Ianus, M. Nilsson, C. M. W. Tax, R. PerezLopez, F. Grussu, Advanced Diffusion-Weighted MRI for Cancer Microstructure
 Assessment in Body Imaging, and Its Relationship With Histology. *J. Magn. Reson. Imaging*(2023), doi:10.1002/jmri.29144.

47. J. H. Jensen, G. Russell Glenn, J. A. Helpern, Fiber ball imaging. Neuroimage. 124, 824-833 1440 1441 (2016).48. E. T. McKinnon, J. A. Helpern, J. H. Jensen, Modeling white matter microstructure with 1442 fiber ball imaging. Neuroimage. 176, 11–21 (2018). 1443 49. W. Warner, M. Palombo, R. Cruz, R. Callaghan, N. Shemesh, D. K. Jones, F. Dell'Acqua, 1444 A. Ianus, I. Drobniak, Temporal Diffusion Ratio (TDR) for imaging restricted diffusion: 1445 Optimisation and pre-clinical demonstration. Neuroimage. 269, 119930 (2023). 1446 50. O. Reynaud, Time-Dependent Diffusion MRI in Cancer: Tissue Modeling and Applications. 1447 Frontiers in Physics. 5 (2017), doi:10.3389/fphy.2017.00058. 1448 51. A. Serrablo, P. Paliogiannis, F. Pulighe, S. S.-M. Moro, V. Borrego-Estella, F. Attene, F. 1449 Scognamillo, C. Hörndler, Impact of novel histopathological factors on the outcomes of liver 1450 surgery for colorectal cancer metastases. Eur. J. Surg. Oncol. 42, 1268–1277 (2016). 1451 52. P. Nuciforo, T. Pascual, J. Cortés, A. Llombart-Cussac, R. Fasani, L. Paré, M. Oliveira, P. 1452 1453 Galvan, N. Martínez, B. Bermejo, M. Vidal, S. Pernas, R. López, M. Muñoz, I. Garau, L. Manso, J. Alarcón, E. Martínez, V. Rodrik-Outmezguine, J. C. Brase, P. Villagrasa, A. Prat, 1454 E. Holgado, A predictive model of pathologic response based on tumor cellularity and 1455 tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-1456 free dual HER2 blockade. Ann. Oncol. 29, 170-177 (2018). 1457 53. D. Gentile, A. Sagona, C. De Carlo, B. Fernandes, E. Barbieri, S. Di Maria Grimaldi, F. 1458 Jacobs, G. Vatteroni, L. Scardina, E. Biondi, V. Vinci, R. M. Trimboli, D. Bernardi, C. 1459 Tinterri, Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy 1460 predict prognosis in breast cancer patients. Breast. 69, 323-329 (2023). 1461 54. H.-H. Lee, A. Papaioannou, D. S. Novikov, E. Fieremans, In vivo observation and 1462 biophysical interpretation of time-dependent diffusion in human cortical gray matter. 1463 1464 Neuroimage. 222, 117054 (2020). 55. J.-P. Fortin, D. Parker, B. Tunc, T. Watanabe, M. A. Elliott, K. Ruparel, D. R. Roalf, T. D. 1465 Satterthwaite, R. C. Gur, R. E. Gur, R. T. Schultz, R. Verma, R. T. Shinohara, 1466 Harmonization of multi-site diffusion tensor imaging data. *Neuroimage*. 161, 149–170 1467 (2017). 1468 56. S. Cetin Karayumak, S. Bouix, L. Ning, A. James, T. Crow, M. Shenton, M. Kubicki, Y. 1469 Rathi, Retrospective harmonization of multi-site diffusion MRI data acquired with different 1470 acquisition parameters. Neuroimage. 184, 180–200 (2019). 1471 57. H. Boonstra, J. W. Oosterhuis, A. M. Oosterhuis, G. J. Fleuren, Cervical tissue shrinkage by 1472 formaldehyde fixation, paraffin wax embedding, section cutting and mounting. Virchows 1473 Arch. A Pathol. Anat. Histopathol. 402, 195–201 (1983). 1474 58. J. Xu, X. Jiang, S. P. Devan, L. R. Arlinghaus, E. T. McKinley, J. Xie, Z. Zu, Q. Wang, A. 1475 B. Chakravarthy, Y. Wang, J. C. Gore, MRI-cytometry: Mapping nonparametric cell size 1476 distributions using diffusion MRI. Magn. Reson. Med. 85, 748-761 (2021). 1477

59. J. Xu, X. Jiang, H. Li, L. R. Arlinghaus, E. T. McKinley, S. P. Devan, B. M. Hardy, J. Xie, 1478 H. Kang, A. B. Chakravarthy, J. C. Gore, Magnetic resonance imaging of mean cell size in 1479 human breast tumors. Magn. Reson. Med. 83, 2002–2014 (2020). 1480 60. O. Reynaud, K. V. Winters, D. M. Hoang, Y. Z. Wadghiri, D. S. Novikov, S. G. Kim, Pulsed 1481 and oscillating gradient MRI for assessment of cell size and extracellular space (POMACE) 1482 in mouse gliomas. NMR Biomed. 29, 1350-1363 (2016). 1483 61. D. Le Bihan, E. Breton, D. Lallemand, P. Grenier, E. Cabanis, M. Laval-Jeantet, MR 1484 imaging of intravoxel incoherent motions: application to diffusion and perfusion in 1485 neurologic disorders. Radiology. 161, 401-407 (1986). 1486 62. Y. T. Li, J.-P. Cercueil, J. Yuan, W. Chen, R. Loffroy, Y. X. J. Wáng, Liver intravoxel 1487 incoherent motion (IVIM) magnetic resonance imaging: a comprehensive review of 1488 published data on normal values and applications for fibrosis and tumor evaluation. Quant. 1489 Imaging Med. Surg. 7, 59–78 (2017). 1490 63. B. Balinov, B. Jonsson, P. Linse, O. Soderman, The NMR Self-Diffusion Method Applied to 1491 Restricted Diffusion. Simulation of Echo Attenuation from Molecules in Spheres and 1492 between Planes. J. Magn. Reson. A. 104, 17-25 (1993). 1493 64. N. P. Jerome, J. A. d'Arcy, T. Feiweier, D.-M. Koh, M. O. Leach, D. J. Collins, M. R. Orton, 1494 Extended T2-IVIM model for correction of TE dependence of pseudo-diffusion volume 1495 fraction in clinical diffusion-weighted magnetic resonance imaging. Phys. Med. Biol. 61, 1496 N667-N680 (2016). 1497 65. J. Veraart, D. S. Novikov, D. Christiaens, B. Ades-Aron, J. Sijbers, E. Fieremans, Denoising 1498 of diffusion MRI using random matrix theory. *Neuroimage*. **142**, 394–406 (2016). 1499 66. E. Kellner, B. Dhital, V. G. Kiselev, M. Reisert, Gibbs-ringing artifact removal based on 1500 local subvoxel-shifts. Magn. Reson. Med. 76, 1574-1581 (2016). 1501 67. E. Garyfallidis, M. Brett, B. Amirbekian, A. Rokem, S. van der Walt, M. Descoteaux, I. 1502 Nimmo-Smith, Dipy Contributors, Dipy, a library for the analysis of diffusion MRI data. 1503 Front. Neuroinform. 8, 8 (2014). 1504 68. S. Ourselin, A. Roche, G. Subsol, X. Pennec, N. Ayache, Reconstructing a 3D structure from 1505 serial histological sections. Image Vis. Comput. 19, 25-31 (2001). 1506 69. J. L. R. Andersson, S. Skare, J. Ashburner, How to correct susceptibility distortions in spin-1507 echo echo-planar images: application to diffusion tensor imaging. Neuroimage. 20, 870-888 1508 (2003). 1509 70. B. B. Avants, C. L. Epstein, M. Grossman, J. C. Gee, Symmetric diffeomorphic image 1510 registration with cross-correlation: evaluating automated labeling of elderly and 1511 neurodegenerative brain. Med. Image Anal. 12, 26-41 (2008). 1512 71. J. Rafael-Patino, D. Romascano, A. Ramirez-Manzanares, E. J. Canales-Rodríguez, G. 1513 Girard, J.-P. Thiran, Robust Monte-Carlo Simulations in Diffusion-MRI: Effect of the 1514 Substrate Complexity and Parameter Choice on the Reproducibility of Results. Front. 1515 Neuroinform. 14, 8 (2020). 1516

Supplementary Materials




Fig. S1: radiological-histological co-localisation of the ex vivo mouse liver data.

Illustration of the radiological-histological co-localisation on the 7 fixed mouse livers obtained from mice implanted with a biopsy from a prostate cancer patient. (A), left: illustrative slice of the high-resolution anatomical T2-weighted fast spin echo. (B), centre: hematoxylin and eosin (HE)stained section, taken from the MRI slice shown to the left. (C), right: detail of the microstructure characterising each specimen, as assessed by an experienced pathologist (SS). Different specimens are arranged along different rows. From top to bottom: *Control*, normal liver structures (no biopsy implantation); Pat_{NA1} and Pat_{NA2} , normal appearing normal liver structures after prostate cancer biopsy implantation; Pat_{inf1} , Pat_{inf2} and Pat_{inf3} : pathology following implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces); Pat_{nec} , pathology following implantation, consisting of necrosis and inflammation.




Fig. S2: MRI-histology Total Correlation Score (TCS) for biophysical dMRI model selection, as obtained when fitting dMRI signal models on the whole image set.

Values of TCS for all models, as obtained by fitting models on the whole image set (set of images with negligible vascular signal contributions, i.e., b > 1000 s/mm² in the fixed mouse livers and b > 100 s/mm² *in vivo*). We evaluated TCS for histology-informed model selection using a sample size of N = 25.






Fig. S3: Biophysical dMRI signal model selection based on BIC and HFC criteria.

Frequency of model selection based on the *Bayesian Information Criterion* (BIC, quantifying how well a model fits the dMRI signals, penalising model complexity) and on the *Histology-fidelity Criterion* (HFC, quantifying how accurately a dMRI models estimates the intra-cellular fraction and the volume-weighted cell size as seen on histology). (A) reports results when models are fitted to the entire set of measurements with negligible vascular signal constributions ($b > 1000 \text{ s/mm}^2$ for suppression of PBS fluid within vessels in the fixed mouse livers; $b > 100 \text{ s/mm}^2$ for IVIM signal suppression *in vivo* on clinical systems), while (**B**) reporting results obtained when fitting models only on high b-value images ($b > 1800 \text{ s/mm}^2$ in the fixed mouse livers; $b > 900 \text{ s/mm}^2$ *in vivo*).






Frequency of selection of each of 5 biophysical dMRI models on 3 MRI-histology data subsets. First column: selection on 7 fixed mouse livers scanned ex vivo on a preclinical 9.4T Bruker system (A and D, left); Second column: selection on 6 liver tumours imaged *in vivo* on a clinical 1.5T Siemens system (B and E, middle); Third column: selection on 12 liver tumours imaged in vivo on a clinical 3T GE system (C and F, right). Plots on top (A to C) refer to dMRI model fitting performed on images where the vascular signal was suppressed ("whole image set fitting", b >1000 s/mm² for suppression of PBS fluid within vessels on the 9.4T; b > 100 s/mm² for IVIM signal suppression on clinical systems). Plots to the bottom (D to F) refer to dMRI model fitting performed on images where both vascular and extra-cellular, extra-vascular signals were suppressed ("high b-value fitting", b > 1800 s/mm² on the 9.4T; b > 900 s/mm² on clinical systems). Violet: models where extra-cellular ADC is larger than intra-cellular ADC; orange: models with no constraints on which is larger between intra-/extra-cellular ADC. The Bayesian Information Criterion (BIC) selects a model depending on the goodness of MRI signal fitting. The Histology Fidelity Criterion (HFC) selects a model depending on the overall agreement between MRI volume-weighted Cell Size (vCS) and intra-cellular fraction (F) with their histology counterparts.






The synthetic environment consisted of meshed spheres of fixed diameter, representing cells, as this is a common biophysical model used in several dMRI techniques (e.g., VERDICT, IMPULSED). We used the synthetic environment to generate dMRI signals via Monte Carlo simulations for each of the 3 dMRI protocols considered in this study (the PGSE protocol used on the ex vivo mouse livers at 9.4T; the PGSE protocol used in patients in vivo at 3T; the DW TRSE protocol used in patients in vivo at 1.5T). Afterwards, we performed performed dMRI model selection on the synthetic signals, following the same procedures implemented for actual ex vivo and *in vivo* dMRI data. We controlled the intra-sphere fraction F by adding gaps of increasing size in-between abutting spheres packed in an ideal cubic lattice. We probed 4 different values of F(approximately equal to 0.197, 0.323, 0.406, 0.523; notice that the maximum theoretical value of F for cubic lattice packing is equal to 0.5236). For each value of F, we varied the cell diameter (8, 16, 22 and 30 μ m), intra-sphere diffusivity (10 linearly-spaced values in the ranges [0.8; 2.6] μ m² ms^{-1} and [0.8; 3.0] $\mu m^2 ms^{-1}$ for the *ex vivo* and *in vivo* protocols respectively) and extra-sphere intrinsic diffusivity (again, 10 linearly-spaced values in the ranges $[0.8; 2.6] \mu m^2 m s^{-1}$ and [0.8;3.0] μ m² ms⁻¹ for the *ex vivo* and *in vivo* protocols respectively), generating a total of 1600 synthetic voxels. Before dMRI signal model fitting, we corrupted synthetic signal with Rician noise at a signal-to-noise ratio (SNR) of 30 on the b = 0 signal s(b=0) (SNR = $s(b=0)/\sigma$, where σ is the noise standard deviation).



Model fitting on whole image set Model fitting on high *b*-value images

Fig. S6: MRI-histology correlations for models with no assumptions on which is larger between intra-cellular and extra-cellular ADC. Matrices illustrating Pearson's correlation coefficients among all possible pairs of MRI and histology metrics. Histological metrics are: intracellular area fraction F_{histo} ; volume-weighted mean cell size index vCS_{histo} ; cell density per unit area CD_{histo} . MRI metrics are: apparent diffusion coefficient ADC; apparent diffusion excess kurtosis K; intra-cellular area fraction F_{MRI} ; volume-weighted mean cell size index vCS_{MRI} ; cell density per unit area CD_{MRI} . Metrics F_{MRI} , vCS_{MRI} and CD_{MRI} were obtained by fitting models with no assumptions on which is larger between intra-cellular and extra-cellular ADC (*Diff-in-ex* and *Diff-in-exTD*). The 4 panels refer to models *Diff-in-ex* and *Diff-in-exTD* fitted according to 2 different strategies. Panel (A): model *Diff-in-ex* fitted on the whole set of measurements with vascular signal suppression (b > 100 s/mm² *in vivo*, b > 1000 s/mm² *ex vivo*); panel (B): model *Diff-in-ex* fitted on high b-value measurements (b > 900 s/mm² *in vivo*, b > 1800 s/mm² *ex vivo*); panel (C): model *Diff-in-exTD* fitted on the whole set of measurements. We calculated correlation coefficients using a sample size of N = 25 (Fig. 1).



Model fitting on whole image set Model fitting on high *b*-value images

Fig. S7: MRI-histology correlations for models where the extra-cellular ADC is constrained to be larger than the intra-cellular ADC. Matrices illustrating Pearson's correlation coefficients among all possible pairs of MRI and histology metrics. Histological metrics are: intra-cellular area fraction F_{histo} ; volume-weighted mean cell size index vCS_{histo} ; cell density per unit area CD_{histo} . MRI metrics are: apparent diffusion coefficient ADC; apparent diffusion excess kurtosis K; intracellular area fraction F_{MRI} ; volume-weighted mean cell size index vCS_{MRI} ; cell density per unit area CD_{MRI} . Metrics F_{MRI} , vCS_{MRI} and CD_{MRI} were obtained by fitting models that assume that the extra-cellular ADC is always larger than the intra-cellular ADC (*Diff-in, Diff-in-exFast* and *Diff-in-exTDFast*). The 6 panels refer to models *Diff-in, Diff-in-exFast* and *Diff-in-exTDFast* fitted

according to 2 different strategies. Panel (**A**): model *Diff-in* fitted on the whole set of measurements with vascular signal suppression ($b > 100 \text{ s/mm}^2$ in vivo, $b > 1000 \text{ s/mm}^2$ ex vivo); panel (**B**): model *Diff-in* fitted on high b-value measurements ($b > 900 \text{ s/mm}^2$ in vivo, $b > 1800 \text{ s/mm}^2$ ex vivo); panel (**C**): model *Diff-in-exFast* fitted on the whole set of measurements with vascular signal suppression; panel (**D**): model *Diff-in-exFast* fitted on high b-value measurements; panel (**E**): model *Diff-in-exTDFast* fitted on the whole set of measurements with vascular signal suppression; panel (**F**): model *Diff-in-exTDFast* fitted on high b-value measurements. We calculated correlation coefficients using a sample size of N = 25 (Fig. 1).






Fig. S8: standard diffusion MRI metrics in fixed mouse livers ex vivo.

(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): standard diffusion metrics, namely ADC (apparent diffusion coefficient) and K (apparent diffusion kurtosis excess). These metrics were obtained by fitting the standard diffusion kurtosis signal representation $s = s_0 \exp(-b ADC + K (b ADC)^2/6)$ to the set of measurements at fixed TE = 45 ms and $\Delta = 30$ ms. From top to bottom, the figure reports maps from 3 specimens, representative of the 3 different microstructural phenotypes seen in our mouse liver data. These are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Patinf*); pathology following biopsy implantation, consisting of necrosis and inflammation (illustrated by case *Patnec*).





(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): metrics from the *Diff-in-exFast* model fitted to the whole DW image set (b-values with negligible vascular signal contributions, i.e., $b > 1000 \text{ s/mm}^2$ on fixed *ex vivo* tissue, to suppress signal from PBS-filled vessels). From left to right: intra-cellular signal fraction F_{MRI} ; volume-weighted cell size index vCS_{MRI} index; cell density per unit volume CD_{MRI} . Maps from 3 specimens are reported along different rows. The specimens are representative of the 3 different microstructural phenotypes seen in our mouse liver data. From top to bottom, these are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case Pat_{inf}); pathology following biopsy implantation, consisting of extended necrosis and inflammation (illustrated by case Pat_{nec}).




Fig. S10: diffusivity metrics from biophysical MRI models in fixed ex vivo mouse livers.

(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): diffusivity metrics from biophysical model *Diff-in-exFast*, namely: intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$; asymptotic extra-cellular diffusion coefficient $D_{E,\infty}$. (C): intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$ from model *Diff-in* fitted to high b-value images $(b > 1800 \text{ s/mm}^2)$. Maps from 3 specimens are reported along different rows. The specimens are representative of the 3 different microstructural phenotypes seen in our mouse liver data. From top to bottom, these are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Patinf*); pathology following biopsy implantation, consisting of extended necrosis and inflammation (illustrated by case *Patinec*).




Fig. S11: standard diffusion MRI metrics in patients in vivo.

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): standard diffusion metrics in the biopsied tumour. Metrics are: apparent diffusion coefficient (*ADC*) and apparent diffusion kurtosis excess (*K*). These were obtained by fitting the standard diffusion kurtosis signal representation $s = s_0 \exp(-b ADC + K (b ADC)^2/6)$ to the set of measurements at fixed, minimum TE and $b > 100 \text{ s/mm}^2$. Maps are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (third and fourth rows from top): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).






Fig. S12: key parametric maps of the Diff-in-exFast model in patients in vivo.

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): salient metrics of the *Diff-in-exFast* model fitted to the whole set of images with negligible vascular signal contributions ($b > 100 \text{ s/mm}^2$). Metrics are shown in the biopsied tumour. From left to right: intra-cellular signal fraction F_{MRI} ; volume-weighted cell size index vCS_{MRI} index; cell density per unit volume CD_{MRI} . Metrics are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (first and second rows from bottom): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).





(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): diffusivity maps from biophysical model *Diff-in-exFast* in the biopsied tumour. Metrics are: intra-cellular cytosolic diffusivity $D_{0,I}$ and asymptotic extra-cellular diffusion coefficient $D_{E,\infty}$. (C): intra-cellular cytosolic diffusivity $D_{0,I}$ for biophysical model *Diff-in* fitted being fitted only to high b-value images (b > 900 s/mm²). Metrics are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (first and second rows from bottom): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).




Fig. S14: immunotherapy response assessment based on *Diff-in* cytosol diffusivity estimates.

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of the intrinsic intra-cellular cytosol diffusivity $D_{0,I}$ within liver tumours at baseline (i.e., before starting immunotherapy), as obtained by fitting model *Diff-in* at high b-value. Left (panel **A**): Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline $D_{0,I}$ (lower or higher than the sample median). The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. Right (panel **B**): results from univariate Cox regression where the baseline $D_{0,I}$ is a continuous predictor of the survival. The panel shows how changes in baseline $D_{0,I}$ modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows 1 - p, with *p* being the probability of progression, while the x-axis shows the time to progression (in days).




Fig. S15: immunotherapy response assessment based on vascular fraction estimates.

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of the vascular signal fraction f_v within liver tumours at baseline (i.e., before starting immunotherapy). The vascular signal fraction f_v was computed in the initial fitting step, which disentangles the vascular from the non-vascular (tissue) signal, before the latter is split into intra-/extra-cellular contributions in the biophysical model fitting step. The same representation layout as in Fig. S6 was used. Left (A): Kaplan-Meier (KM) analysis, log-rank sum test and Cox regression based on the binarised f_v (higher/lower than the sample median). Right (B): Cox regression modelling the probability of survival as a continuous function of baseline f_v . In all panels, the y-axis shows 1 - p, with p being the probability of progression, while the x-axis shows the time to progression (in days).




Fig. S16: immunotherapy response assessment based on Diff-in-exFast MRI metrics.

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of all *Diff-in-exFast* metrics within liver tumours at baseline (i.e., before starting immunotherapy). In each row, from top to bottom: PFS based on baseline volume-weighted Cell Size vCS (panels A and B), Cell Density CD (panels C and D), intra-cellular fraction F (panels E

and **F**), intrinsic intra-cellular cytosol diffusivity $D_{0,I}$ (panels **G** and **H**), asymptotic extra-cellular diffusion coefficient $D_{E,\infty}$ (panels **I** and **J**). The same representation layout as in Fig. S6 was used. Left (**A**, **C**, **E**, **G**, **I**): Kaplan-Meier (KM) analysis, log-rank sum test and Cox regression based on the binarised MRI metrics (higher/lower than the sample median). Right (**B**, **D**, **F**, **H**, **J**): Cox regression modelling the probability of survival as a continuous function of baseline MRI metrics. In all panels, the y-axis shows 1 - p, with *p* being the probability of progression, while the x-axis shows the time to progression (in days).




Fig. S17: schematic of the dMRI sequences used in this study.

(A): pulsed gradient spin echo (PGSE sequence, also known as Stejskal-Tanner sequence, pulsedfield gradient (PFG), or single linear diffusion encoding) used to acquire data on the 9.4T Bruker system on fixed mouse livers *ex vivo* and on the 3T GE system on patients *in vivo*. δ and Δ respectively indicate the diffusion gradient duration and separation, while TE is the echo time. (**B**): twice-refocussed diffusion-weighted spin echo sequence used to acquire data on the 1.5T Siemens system on patients *in vivo*. δ_n and $\Delta_{n,m}$ respectively indicate the duration of the *n*-th gradient lobe and the separation time between the *n*-th and *m*-th gradient lobes, for n,m = 1, ..., 4. TE is again the echo time. In both panels, "Signal readout" corresponds to sampling the center of the k-space (i.e., zero spatial frequency).

Table S1: results of the model selection based on the Total Correlation Score (TCS) as obtained on simulated dMRI signals.

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals ("Regular fit": fitting on all b-values with negligible vascular contributions; "High *b* only fit": fitting on b-values minimising extra-cellular signal contributions). The Table reports the value of $TCS = r(vCS_{est}, vCS_{gt}) + r(F_{est}, F_{gt})$, where vCS is the cell size, *F* the intra-cellular fraction, r(x,y) the Pearson's correlation between variables *x* and *y* computed pooling together all synthetic voxels, and where subscripts *est* and *gt* respectively indicate estimated and ground truth values. Higher values of TCS point towards better model performance. For each protocol and fitting strategy, the model with the highest TCS is flagged by gray shadowing and bold font.

	Protocol: ex vivo		Prote in vivo		Protocol: in vivo TRSE		
	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	
Model							
Diff-in-exTD	0.217	-0.111	0.312	0.202	0.604	0.483	
Diff-in-ex	0.406	0.089	0.472	0.335	0.700	0.550	
Diff-in-exTDFast	0.948	0.827	0.536	0.336	0.618	0.544	
Diff-in-exFast	0.952	0.850	0.563	0.349	0.626	0.547	
Diff-in	1.222	0.977	0.773	0.462	0.543	0.630	

Table S2: results of the model selection based on the Histology Fidelity Criterion (HFC) as obtained on simulated dMRI signals.

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals ("Regular fit": fitting on all b-values with negligible vascular contributions; "High *b* only fit": fitting on b-values minimising extra-cellular signal contributions). For each model, the table reports the percentage of synthetic voxels where $HFC = |vCS_{est} - vCS_{gt}|/vCS_{gt} + |F_{est} - F_{gt}|/F_{gt}$ was the lowest across all models. Above, *vCS* is the cell size, *F* the intra-cellular fraction, and subscripts *est* and *gt* respectively indicate estimated and ground truth values. Higher percentages indicate smaller estimation errors, and therefore point towards better model performance. For each protocol and fitting strategy, the model with the highest proportion of synthetic voxels with minimum HFC is flagged by gray shadowing and bold font.

	Protocol: ex vivo			ocol: PGSE	Protocol: in vivo TRSE		
	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	
Model							
Diff-in-exTD	12.62%	13.56%	21.69%	22.10%	26.69%	20.69%	
Diff-in-ex	21.19%	16.62%	25.94%	20.35%	28.94%	24.31%	
Diff-in-exTDFast	15.50%	14.94%	10.75%	12.27%	19.69%	14.69%	
Diff-in-exFast	21.81%	10.50%	22.25%	11.33%	19.12%	12.12%	
Diff-in	28.88%	44.38%	19.38%	33.94%	5.56%	28.19%	

Table S3: results of the model selection based on the Bayesian Information Criterion (BIC) as obtained on simulated dMRI signals.

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals ("Regular fit": fitting on all b-values with negligible vascular contributions; "High *b* only fit": fitting on b-values minimising extra-cellular signal contributions). For each model, the table reports the percentage of synthetic voxels where the Bayesian Information Criterion (BIC, a standard metric of model fitting quality that penalises model complexity) was the lowest across all models. Higher percentages indicate smaller BIC values across synthetic voxels, and therefore point towards better model fitting quality. For each protocol and fitting strategy, the model with the highest proportion of synthetic voxels with minimum HFC is flagged by gray shadowing and bold font.

	Protocol: ex vivo			ocol: PGSE	Protocol: in vivo TRSE	
	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit
Model						
Diff-in-exTD	0.12%	0.00%	0.00%	0.19%	0.00%	0.00%
Diff-in-ex	31.25%	15.88%	17.44%	4.69%	40.69%	13.69%
Diff-in-exTDFast	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Diff-in-exFast	3.44%	0.06%	6.69%	0.00%	21.38%	1.06%
Diff-in	65.19%	84.06%	75.88%	95.12%	38.00%	85.25%

Table S4: descriptive statistics of histology and MRI metrics in the fixed mouse livers.

The table reports mean and standard deviation (within brackets) of histology and dMRI metrics in the 7 fixed mouse livers that were scanned on a 9.4T Bruker system. Histological maps were computed within patches matching the in-plane MRI resolution and then warped non-linearly to dMRI space. The histological maps are: per-patch intra-cellular area fraction F_{histo} , per-patch arithmetic mean cell size aCS_{histo} ; per-patch volume-weighted mean cell size vCS_{histo} , cell density per unit patch area CD_{histo} . dMRI metrics are: apparent diffusion coefficient ADC, apparent diffusion kurtosis excess K, intra-cellular signal fraction F_{MRI} , volume-weighted cell size index vCS_{MRI} , apparent cell density per unit volume CD_{MRI} . Metrics F_{MRI} , vCS_{MRI} and CD_{MRI} are reported for both models Diff-in-exFast and model Diff-in, with Diff-in fitted only to high b-value images ($b > 1800 \text{ s/mm}^2$). In model Diff-in-exFast, the extra-cellular signal is modelled as negligible compared to the intra-cellular one (i.e., total signal dominated by intra-cellular water). Specimens are: *Control* (normal liver structures); NA1 and NA2 (normal appearing cases, i.e., normal liver structures despite subcutaneous biopsy implantation); Pat_{infl-3} (cases developing liver pathology following sub-cutaneous biopsy implantation, consisting of necrosis and inflammation). aCS_{histo} , always considerably lower than vCS_{histo} , was included to highlight the impact of the largest cells in the computation of statistics based on weighting by cell volume (vCS_{histo}).

		Histology			Standard diffusion metrics		Diff-in-exFast model			Diff-in model at high b		
Specimen	F_{histo}	aCS _{histo} [µm]	vCS _{histo} [µm]	CD _{histo} /10 ² [cell/mm ²]	ADC [µm²/ms]	K	F_{MRI}	vCS _{MRI} [µm]	CD _{MRI} /10 ⁵ [cell/mm ³]	F_{MRI}	v <i>CS_{MRI}</i> [µm]	CD _{MRI} /10 ⁵ [cell/mm ³]
Control	0.75	21.63	27.1	3.2	1.50	0.33	0.60	33.2	0.38	0.56	36.5	0.28
	(0.18)	(1.85)	(1.6)	(1.1)	(0.32)	(0.20)	(0.18)	(5.7)	(1.69)	(0.11)	(5.1)	(1.44)
NA1	0.59	23.97	27.8	2.1	1.61	0.10	0.66	30.5	0.69	0.54	32.2	0.45
	(0.25)	(3.05)	(3.2)	(1.1)	(0.37)	(0.15)	(0.25)	(8.4)	(2.18)	(0.16)	(7.5)	(1.68)
NA2	0.76	23.46	29.4	2.7	1.43	0.51	0.80	22.2	1.01	0.71	22.8	0.83
	(0.14)	(1.41)	(1.2)	(0.7)	(0.44)	(0.29)	(0.16)	(4.8)	(1.35)	(0.12)	(5.0)	(1.15)
Pat _{inf1}	0.80	15.73	20.8	6.7	0.58	0.98	0.83	13.4	4.20	0.77	12.4	4.86
	(0.20)	(2.18)	(2.7)	(2.2)	(0.41)	(0.49)	(0.13)	(3.1)	(2.22)	(0.14)	(3.0)	(2.27)
Pat _{inf2}	0.79	21.41	26.8	3.5	1.67	0.17	0.37	31.2	0.44	0.41	37.1	0.30
	(0.20)	(2.29)	(2.7)	(1.2)	(0.39)	(0.17)	(0.22)	(7.5)	(2.06)	(0.14)	(6.0)	(1.57)
Pat _{inf3}	0.70	20.95	27.6	3.1	1.57	0.43	0.63	23.6	1.27	0.59	24.2	0.97
	(0.27)	(1.75)	(1.7)	(1.3)	(0.62)	(0.31)	(0.23)	(8.8)	(2.62)	(0.20)	(8.0)	(2.01)
Patnec	0.52	19.10	25.9	3.4	1.49	0.31	0.61	28.2	0.58	0.54	31.6	0.42
	(0.25)	(3.33)	(2.8)	(2.3)	(0.44)	(0.22)	(0.23)	(6.6)	(1.93)	(0.16)	(6.7)	(1.66)

Table S5. Hazard ratios obtained from Cox regression models controlling for sex, age, and baseline tumour volume.

The table reports the Hazard Ratios (HR) for different MRI metrics, with relative 95% confidence interval and p-value, estimated through Cox proportional hazard regressions. The models assessed the dependence of the probability of progression on the baseline mean value of MRI metrics within liver tumours, accounting for sex, age and tumour volume. Results are shown for standard diffusion metrics (apparent diffusion and excess kurtosis coefficients, *ADC* and *K*), for the vascular signal fraction f_v , for metrics from model *DiffinexFast* (intra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$, extra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular diffusion per unit volume *CD*, intrinsic intra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular signal fraction *F*. Solume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular signal fraction *F*.

	HR of	HR of	HR of	HR of tumour				
	MRI metric	male sex	age	volume				
Standard diffusion MRI metrics								
ADC	1.00 (0.67;	0.71 (0.32;	0.97 (0.94;	0.32 (0.06;				
	1.49); <i>p</i> = 1.00	1.55; $p = 0.39$	(0.99); p = 0.02	1.70); <i>p</i> = 0.18				
K	1.36 (0.94;	0.64 (0.29;	0.97 (0.94;	0.35 (0.08;				
	1.97); <i>p</i> = 0.11	1.41; $p = 0.27$	1.00); p = 0.02	1.54); <i>p</i> = 0.17				
Other met	rics (from vascul	ar vs non-vascul	ar fitting initialis	ation step)				
f_v	1.16 (0.79;	0.77 (0.35;	0.96 (0.93;	0.34 (0.17;				
	1.71); $p = 0.44$	1.68); $p = 0.51$	(0.99); p = 0.01	2.56); <i>p</i> = 0.17				
	Metrics from	m MRI model <i>Di</i>	ff-in-exFast					
F	0.87 (0.61;	0.78 (0.35;	0.97 (0.94;	0.31 (0.06;				
	1.26); <i>p</i> = 0.46	1.72); $p = 0.54$	1.00); p = 0.02	1.58); <i>p</i> = 0.16				
vCS	0.70 (0.44;	0.78 (0.36;	0.97 (0.94;	0.35 (0.08;				
	1.12); <i>p</i> = 0.14	1.68); <i>p</i> = 0.53	(0.99); p = 0.02	1.46); <i>p</i> = 0.15				
CD	1.53 (1.00;	0.63 (0.29;	0.96 (0.93;	0.32 (0.06;				
	2.34); $p = 0.05$	1.38); <i>p</i> = 0.25	(0.99); p = 0.01	1.81); <i>p</i> = 0.20				
$D_{0,I}$	1.45 (0.98;	0.68 (0.31;	0.96 (0.93;	0.36 (0.09;				
	2.14); <i>p</i> = 0.06	1.47); <i>p</i> = 0.33	(0.99); p = 0.01	1.35); <i>p</i> = 0.13				
$D_{E,\infty}$	1.41 (0.97;	0.69 (0.32;	0.96 (0.94;	0.40 (0.13;				
	2.05); <i>p</i> = 0.07	1.48; $p = 0.34$	(0.99); p = 0.01	1.26); <i>p</i> = 0.12				
Metrics from MRI model <i>Diff-in</i> fitted to high <i>b</i> -value images								
F	0.79 (0.54;	0.80 (0.36;	0.97 (0.94;	0.33 (0.07;				
	1.17); <i>p</i> = 0.24	1.74); <i>p</i> = 0.57	(0.99); p = 0.02	1.49); <i>p</i> = 0.15				
vCS	0.59 (0.37;	0.66 (0.30;	0.96 (0.94;	0.40 (0.12;				
	0.93); $p = 0.02$	1.43); <i>p</i> = 0.29	(0.99); p = 0.01	1.37); <i>p</i> = 0.14				
CD	1.65 (1.12;	0.61 (0.28;	0.96 (0.93;	0.36 (0.09;				
	2.44); <i>p</i> = 0.01	1.35); <i>p</i> = 0.22	(0.99); p = 0.01	1.52); <i>p</i> = 0.17				
$D_{0,I}$	1.28 (0.82;	0.67 (0.31;	0.96 (0.94;	0.37 (0.09;				
	1.98); <i>p</i> = 0.28	1.45); $p = 0.31$	(0.99); p = 0.01	1.48); <i>p</i> = 0.16				